1
|
Kamadjou A, Decock A, Huleux T, Depreux A, Aissi E, Landre L, Baclet V, Viget N, Valette M, Robineau O, Meybeck A. Impact of the COVID-19 pandemic on sexual behaviour and welfare of HIV preexposure prophylaxis users: a mixed-method study. AIDS Care 2024; 36:343-350. [PMID: 37128640 DOI: 10.1080/09540121.2023.2206100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Accepted: 04/17/2023] [Indexed: 05/03/2023]
Abstract
COVID-19 pandemic can affect people using HIV preexposure prophylaxis (PrEP). To assess its consequences on PrEP users' sexual behaviour and welfare, we conducted a mixed-method study. A self-administered questionnaire was given to PrEP users during scheduled consultation in Tourcoing Hospital from February to May 2021. In addition, a qualitative study included 14 participants who took part in semi-structured in-depth interviews (IDIs). Ninety-four PrEP users completed the questionnaire. During lockdown, 62% of participants continued PrEP. After lockdown release, the average number of sexual intercourses and partners increased from 6 ± 12 to 13 ± 17 intercourses/month (p < 0.001) and from 3 ± 11 to 11 ± 34 partners/month (p < 0.001). Similarly, the proportion of PrEP users who engaged in group sex, sex with alcohol or chemsex increased respectively from 28% to 55% (p < 0.001), 28% to 45% (p < 0.001) and 28% to 38% (p < 0.001). Analysis of IDIs revealed emotional deprivation and sexual frustration during the lockdown. After its release, frequent clandestine chemsex parties and curfew forcing overnight stay increased fears of intimate violence and overdoses. In conclusion, PrEP users reduced their sexual activity during the lockdown. Its release led to an increase in sexual risk-taking. Social distancing measures could favour medical and social harm of sexual risk-taking.
Collapse
Affiliation(s)
- Audrey Kamadjou
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
| | - Anna Decock
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
- Sexual Health Clinic, Tourcoing Hospital, Tourcoing, France
| | - Thomas Huleux
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
- Sexual Health Clinic, Tourcoing Hospital, Tourcoing, France
| | - Alma Depreux
- Sexual Health Clinic, Tourcoing Hospital, Tourcoing, France
| | - Emmanuelle Aissi
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
- Sexual Health Clinic, Tourcoing Hospital, Tourcoing, France
| | - Laura Landre
- Sexual Health Clinic, Tourcoing Hospital, Tourcoing, France
| | - Véronique Baclet
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
- Sexual Health Clinic, Tourcoing Hospital, Tourcoing, France
| | - Nathalie Viget
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
- Sexual Health Clinic, Tourcoing Hospital, Tourcoing, France
| | - Michel Valette
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
- Sexual Health Clinic, Tourcoing Hospital, Tourcoing, France
| | - Olivier Robineau
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
| | - Agnès Meybeck
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
| |
Collapse
|
2
|
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C, Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, de Tejada BM, Marzolini C, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rudin C, Schöni-Affolter F, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Weber R, Yerly S, van der Valk M, Geerlings SE, Goorhuis A, Hovius JW, Lempkes B, Nellen FJB, van der Poll T, Prins JM, Reiss P, van Vugt M, Wiersinga WJ, Wit FWMN, van Duinen M, van Eden J, Hazenberg A, van Hes AMH, Rajamanoharan S, Robinson T, Taylor B, Brewer C, Mayr C, Schmidt W, Speidel A, Strohbach F, Arastéh K, Cordes C, Pijnappel FJJ, Stündel M, Claus J, Baumgarten A, Carganico A, Ingiliz P, Dupke S, Freiwald M, Rausch M, Moll A, Schleehauf D, Smalhout SY, Hintsche B, Klausen G, Jessen H, Jessen A, Köppe S, Kreckel P, Schranz D, Fischer K, Schulbin H, Speer M, Weijsenfeld AM, Glaunsinger T, Wicke T, Bieniek B, Hillenbrand H, Schlote F, Lauenroth-Mai E, Schuler C, Schürmann D, Wesselmann H, Brockmeyer N, Jurriaans S, Gehring P, Schmalöer D, Hower M, Spornraft-Ragaller P, Häussinger D, Reuter S, Esser S, Markus R, Kreft B, Berzow D, Back NKT, Christl A, Meyer A, Plettenberg A, Stoehr A, Graefe K, Lorenzen T, Adam A, Schewe K, Weitner L, Fenske S, Zaaijer HL, Hansen S, Stellbrink HJ, Wiemer D, Hertling S, Schmidt R, Arbter P, Claus B, Galle P, Jäger H, Jä Gel-Guedes E, Berkhout B, Postel N, Fröschl M, Spinner C, Bogner J, Salzberger B, Schölmerich J, Audebert F, Marquardt T, Schaffert A, Schnaitmann E, Cornelissen MTE, Trein A, Frietsch B, Müller M, Ulmer A, Detering-Hübner B, Kern P, Schubert F, Dehn G, Schreiber M, Güler C, Schinkel CJ, Gunsenheimer-Bartmeyer B, Schmidt D, Meixenberger K, Bannert N, Wolthers KC, Peters EJG, van Agtmael MA, Autar RS, Bomers M, Sigaloff KCE, Heitmuller M, Laan LM, Ang CW, van Houdt R, Jonges M, Kuijpers TW, Pajkrt D, Scherpbier HJ, de Boer C, van der Plas A, van den Berge M, Stegeman A, Baas S, Hage de Looff L, Buiting A, Reuwer A, Veenemans J, Wintermans B, Pronk MJH, Ammerlaan HSM, van den Bersselaar DNJ, de Munnik ES, Deiman B, Jansz AR, Scharnhorst V, Tjhie J, Wegdam MCA, van Eeden A, Nellen J, Brokking W, Elsenburg LJM, Nobel H, van Kasteren MEE, Berrevoets MAH, Brouwer AE, Adams A, van Erve R, de Kruijf-van de Wiel BAFM, Keelan-Phaf S, van de Ven B, van der Ven B, Buiting AGM, Murck JL, de Vries-Sluijs TEMS, Bax HI, van Gorp ECM, de Jong-Peltenburg NC, de Mendonç A Melo M, van Nood E, Nouwen JL, Rijnders BJA, Rokx C, Schurink CAM, Slobbe L, Verbon A, Bassant N, van Beek JEA, Vriesde M, van Zonneveld LM, de Groot J, Boucher CAB, Koopmans MPG, van Kampen JJA, Fraaij PLA, van Rossum AMC, Vermont CL, van der Knaap LC, Visser E, Branger J, Douma RA, Cents-Bosma AS, Duijf-van de Ven CJHM, Schippers EF, van Nieuwkoop C, van Ijperen JM, Geilings J, van der Hut G, van Burgel ND, Leyten EMS, Gelinck LBS, Mollema F, Davids-Veldhuis S, Tearno C, Wildenbeest GS, Heikens E, Groeneveld PHP, Bouwhuis JW, Lammers AJJ, Kraan S, van Hulzen AGW, Kruiper MSM, van der Bliek GL, Bor PCJ, Debast SB, Wagenvoort GHJ, Kroon FP, de Boer MGJ, Jolink H, Lambregts MMC, Roukens AHE, Scheper H, Dorama W, van Holten N, Claas ECJ, Wessels E, den Hollander JG, El Moussaoui R, Pogany K, Brouwer CJ, Smit JV, Struik-Kalkman D, van Niekerk T, Pontesilli O, Lowe SH, Oude Lashof AML, Posthouwer D, van Wolfswinkel ME, Ackens RP, Burgers K, Schippers J, Weijenberg-Maes B, van Loo IHM, Havenith TRA, van Vonderen MGA, Kampschreur LM, Faber S, Steeman-Bouma R, Al Moujahid A, Kootstra GJ, Delsing CE, van der Burg-van de Plas M, Scheiberlich L, Kortmann W, van Twillert G, Renckens R, Ruiter-Pronk D, van Truijen-Oud FA, Cohen Stuart JWT, Jansen ER, Hoogewerf M, Rozemeijer W, van der Reijden WA, Sinnige JC, Brinkman K, van den Berk GEL, Blok WL, Lettinga KD, de Regt M, Schouten WEM, Stalenhoef JE, Veenstra J, Vrouenraets SME, Blaauw H, Geerders GF, Kleene MJ, Kok M, Knapen M, van der Meché IB, Mulder-Seeleman E, Toonen AJM, Wijnands S, Wttewaal E, Kwa D, van Crevel R, van Aerde K, Dofferhoff ASM, Henriet SSV, Ter Hofstede HJM, Hoogerwerf J, Keuter M, Richel O, Albers M, Grintjes-Huisman KJT, de Haan M, Marneef M, Strik-Albers R, Rahamat-Langendoen J, Stelma FF, Burger D, Gisolf EH, Hassing RJ, Claassen M, Ter Beest G, van Bentum PHM, Langebeek N, Tiemessen R, Swanink CMA, van Lelyveld SFL, Soetekouw R, van der Prijt LMM, van der Swaluw J, Bermon N, van der Reijden WA, Jansen R, Herpers BL, Veenendaal D, Verhagen DWM, Lauw FN, van Broekhuizen MC, van Wijk M, Bierman WFW, Bakker M, Kleinnijenhuis J, Kloeze E, Middel A, Postma DF, Schölvinck EH, Stienstra Y, Verhage AR, Wouthuyzen-Bakker M, Boonstra A, de Groot-de Jonge H, van der Meulen PA, de Weerd DA, Niesters HGM, van Leer-Buter CC, Knoester M, Hoepelman AIM, Arends JE, Barth RE, Bruns AHW, Ellerbroek PM, Mudrikova T, Oosterheert JJ, Schadd EM, van Welzen BJ, Aarsman K, Griffioen-van Santen BMG, de Kroon I, van Berkel M, van Rooijen CSAM, Schuurman R, Verduyn-Lunel F, Wensing AMJ, Bont LJ, Geelen SPM, Loeffen YGT, Wolfs TFW, Nauta N, Rooijakkers EOW, Holtsema H, Voigt R, van de Wetering D, Alberto A, van der Meer I, Rosingh A, Halaby T, Zaheri S, Boyd AC, Bezemer DO, van Sighem AI, Smit C, Hillebregt M, de Jong A, Woudstra T, Bergsma D, Meijering R, van de Sande L, Rutkens T, van der Vliet S, de Groot L, van den Akker M, Bakker Y, El Berkaoui A, Bezemer M, Brétin N, Djoechro E, Groters M, Kruijne E, Lelivelt KJ, Lodewijk C, Lucas E, Munjishvili L, Paling F, Peeck B, Ree C, Regtop R, Ruijs Y, Schoorl M, Schnörr P, Scheigrond A, Tuijn E, Veenenberg L, Visser KM, Witte EC, Ruijs Y, Van Frankenhuijsen M, Allegre T, Makhloufi D, Livrozet JM, Chiarello P, Godinot M, Brunel-Dalmas F, Gibert S, Trepo C, Peyramond D, Miailhes P, Koffi J, Thoirain V, Brochier C, Baudry T, Pailhes S, Lafeuillade A, Philip G, Hittinger G, Assi A, Lambry V, Rosenthal E, Naqvi A, Dunais B, Cua E, Pradier C, Durant J, Joulie A, Quinsat D, Tempesta S, Ravaux I, Martin IP, Faucher O, Cloarec N, Champagne H, Pichancourt G, Morlat P, Pistone T, Bonnet F, Mercie P, Faure I, Hessamfar M, Malvy D, Lacoste D, Pertusa MC, Vandenhende MA, Bernard N, Paccalin F, Martell C, Roger-Schmelz J, Receveur MC, Duffau P, Dondia D, Ribeiro E, Caltado S, Neau D, Dupont M, Dutronc H, Dauchy F, Cazanave C, Vareil MO, Wirth G, Le Puil S, Pellegrin JL, Raymond I, Viallard JF, Chaigne de Lalande S, Garipuy D, Delobel P, Obadia M, Cuzin L, Alvarez M, Biezunski N, Porte L, Massip P, Debard A, Balsarin F, Lagarrigue M, Prevoteau du Clary F, Aquilina C, Reynes J, Baillat V, Merle C, Lemoing V, Atoui N, Makinson A, Jacquet JM, Psomas C, Tramoni C, Aumaitre H, Saada M, Medus M, Malet M, Eden A, Neuville S, Ferreyra M, Sotto A, Barbuat C, Rouanet I, Leureillard D, Mauboussin JM, Lechiche C, Donsesco R, Cabie A, Abel S, Pierre-Francois S, Batala AS, Cerland C, Rangom C, Theresine N, Hoen B, Lamaury I, Fabre I, Schepers K, Curlier E, Ouissa R, Gaud C, Ricaud C, Rodet R, Wartel G, Sautron C, Beck-Wirth G, Michel C, Beck C, Halna JM, Kowalczyk J, Benomar M, Drobacheff-Thiebaut C, Chirouze C, Faucher JF, Parcelier F, Foltzer A, Haffner-Mauvais C, Hustache Mathieu M, Proust A, Piroth L, Chavanet P, Duong M, Buisson M, Waldner A, Mahy S, Gohier S, Croisier D, May T, Delestan M, Andre M, Zadeh MM, Martinot M, Rosolen B, Pachart A, Martha B, Jeunet N, Rey D, Cheneau C, Partisani M, Priester M, Bernard-Henry C, Batard ML, Fischer P, Berger JL, Kmiec I, Robineau O, Huleux T, Ajana F, Alcaraz I, Allienne C, Baclet V, Meybeck A, Valette M, Viget N, Aissi E, Biekre R, Cornavin P, Merrien D, Seghezzi JC, Machado M, Diab G, Raffi F, Bonnet B, Allavena C, Grossi O, Reliquet V, Billaud E, Brunet C, Bouchez S, Morineau-Le Houssine P, Sauser F, Boutoille D, Besnier M, Hue H, Hall N, Brosseau D, Souala F, Michelet C, Tattevin P, Arvieux C, Revest M, Leroy H, Chapplain JM, Dupont M, Fily F, Patra-Delo S, Lefeuvre C, Bernard L, Bastides F, Nau P, Verdon R, de la Blanchardiere A, Martin A, Feret P, Geffray L, Daniel C, Rohan J, Fialaire P, Chennebault JM, Rabier V, Abgueguen P, Rehaiem S, Luycx O, Niault M, Moreau P, Poinsignon Y, Goussef M, Mouton-Rioux V, Houlbert D, Alvarez-Huve S, Barbe F, Haret S, Perre P, Leantez-Nainville S, Esnault JL, Guimard T, Suaud I, Girard JJ, Simonet V, Debab Y, Schmit JL, Jacomet C, Weinberck P, Genet C, Pinet P, Ducroix S, Durox H, Denes É, Abraham B, Gourdon F, Antoniotti O, Molina JM, Ferret S, Lascoux-Combe C, Lafaurie M, Colin de Verdiere N, Ponscarme D, De Castro N, Aslan A, Rozenbaum W, Pintado C, Clavel F, Taulera O, Gatey C, Munier AL, Gazaigne S, Penot P, Conort G, Lerolle N, Leplatois A, Balausine S, Delgado J, Timsit J, Tabet M, Gerard L, Girard PM, Picard O, Tredup J, Bollens D, Valin N, Campa P, Bottero J, Lefebvre B, Tourneur M, Fonquernie L, Wemmert C, Lagneau JL, Yazdanpanah Y, Phung B, Pinto A, Vallois D, Cabras O, Louni F, Pialoux G, Lyavanc T, Berrebi V, Chas J, Lenagat S, Rami A, Diemer M, Parrinello M, Depond A, Salmon D, Guillevin L, Tahi T, Belarbi L, Loulergue P, Zak Dit Zbar O, Launay O, Silbermann B, Leport C, Alagna L, Pietri MP, Simon A, Bonmarchand M, Amirat N, Pichon F, Kirstetter M, Katlama C, Valantin MA, Tubiana R, Caby F, Schneider L, Ktorza N, Calin R, Merlet A, Ben Abdallah S, Weiss L, Buisson M, Batisse D, Karmochine M, Pavie J, Minozzi C, Jayle D, Castel P, Derouineau J, Kousignan P, Eliazevitch M, Pierre I, Collias L, Viard JP, Gilquin J, Sobel A, Slama L, Ghosn J, Hadacek B, Thu-Huyn N, Nait-Ighil L, Cros A, Maignan A, Duvivier C, Consigny PH, Lanternier F, Shoai-Tehrani M, Touam F, Jerbi S, Bodard L, Jung C, Goujard C, Quertainmont Y, Duracinsky M, Segeral O, Blanc A, Peretti D, Cheret A, Chantalat C, Dulucq MJ, Levy Y, Lelievre JD, Lascaux AS, Dumont C, Boue F, Chambrin V, Abgrall S, Kansau I, Raho-Moussa M, De Truchis P, Dinh A, Davido B, Marigot D, Berthe H, Devidas A, Chevojon P, Chabrol A, Agher N, Lemercier Y, Chaix F, Turpault I, Bouchaud O, Honore P, Rouveix E, Reimann E, Belan AG, Godin Collet C, Souak S, Mortier E, Bloch M, Simonpoli AM, Manceron V, Cahitte I, Hiraux E, Lafon E, Cordonnier F, Zeng AF, Zucman D, Majerholc C, Bornarel D, Uludag A, Gellen-Dautremer J, Lefort A, Bazin C, Daneluzzi V, Gerbe J, Jeantils V, Coupard M, Patey O, Bantsimba J, Delllion S, Paz PC, Cazenave B, Richier L, Garrait V, Delacroix I, Elharrar B, Vittecoq D, Bolliot C, Lepretre A, Genet P, Masse V, Perrone V, Boussard JL, Chardon P, Froguel E, Simon P, Tassi S, Avettand Fenoel V, Barin F, Bourgeois C, Cardon F, Chaix ML, Delfraissy JF, Essat A, Fischer H, Lecuroux C, Meyer L, Petrov-Sanchez V, Rouzioux C, Saez-Cirion A, Seng R, Kuldanek K, Mullaney S, Young C, Zucchetti A, Bevan MA, McKernan S, Wandolo E, Richardson C, Youssef E, Green P, Faulkner S, Faville R, Herman S, Care C, Blackman H, Bellenger K, Fairbrother K, Phillips A, Babiker A, Delpech V, Fidler S, Clarke M, Fox J, Gilson R, Goldberg D, Hawkins D, Johnson A, Johnson M, McLean K, Nastouli E, Post F, Kennedy N, Pritchard J, Andrady U, Rajda N, Donnelly C, McKernan S, Drake S, Gilleran G, White D, Ross J, Harding J, Faville R, Sweeney J, Flegg P, Toomer S, Wilding H, Woodward R, Dean G, Richardson C, Perry N, Gompels M, Jennings L, Bansaal D, Browing M, Connolly L, Stanley B, Estreich S, Magdy A, O'Mahony C, Fraser P, Jebakumar SPR, David L, Mette R, Summerfield H, Evans M, White C, Robertson R, Lean C, Morris S, Winter A, Faulkner S, Goorney B, Howard L, Fairley I, Stemp C, Short L, Gomez M, Young F, Roberts M, Green S, Sivakumar K, Minton J, Siminoni A, Calderwood J, Greenhough D, DeSouza C, Muthern L, Orkin C, Murphy S, Truvedi M, McLean K, Hawkins D, Higgs C, Moyes A, Antonucci S, McCormack S, Lynn W, Bevan M, Fox J, Teague A, Anderson J, Mguni S, Post F, Campbell L, Mazhude C, Russell H, Gilson R, Carrick G, Ainsworth J, Waters A, Byrne P, Johnson M, Fidler S, Kuldanek K, Mullaney S, Lawlor V, Melville R, Sukthankar A, Thorpe S, Murphy C, Wilkins E, Ahmad S, Green P, Tayal S, Ong E, Meaden J, Riddell L, Loay D, Peacock K, Blackman H, Harindra V, Saeed AM, Allen S, Natarajan U, Williams O, Lacey H, Care C, Bowman C, Herman S, Devendra SV, Wither J, Bridgwood A, Singh G, Bushby S, Kellock D, Young S, Rooney G, Snart B, Currie J, Fitzgerald M, Arumainayyagam J, Chandramani S. A highly virulent variant of HIV-1 circulating in the Netherlands. Science 2022; 375:540-545. [PMID: 35113714 DOI: 10.1126/science.abk1688] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.
Collapse
Affiliation(s)
- Chris Wymant
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | | | - François Blanquart
- Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, PSL Research University, Paris, France.,IAME, UMR 1137, INSERM, Université de Paris, Paris, France
| | - Luca Ferretti
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Astrid Gall
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
| | - Matthew Hall
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Tanya Golubchik
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Margreet Bakker
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Swee Hoe Ong
- Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK
| | - Lele Zhao
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - David Bonsall
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Mariateresa de Cesare
- Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - George MacIntyre-Cockett
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Lucie Abeler-Dörner
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Jan Albert
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.,Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
| | - Norbert Bannert
- Division for HIV and Other Retroviruses, Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany
| | - Jacques Fellay
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.,Swiss Institute of Bioinformatics, Lausanne, Switzerland.,Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - M Kate Grabowski
- Department of Pathology, John Hopkins University, Baltimore, MD, USA
| | | | - Huldrych F Günthard
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.,Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | - Pia Kivelä
- Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland
| | - Roger D Kouyos
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.,Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | | | - Laurence Meyer
- INSERM CESP U1018, Université Paris Saclay, APHP, Service de Santé Publique, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - Kholoud Porter
- Institute for Global Health, University College London, London, UK
| | - Matti Ristola
- Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland
| | | | - Ben Berkhout
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Paul Kellam
- Kymab Ltd., Cambridge, UK.,Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK
| | - Marion Cornelissen
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.,Molecular Diagnostic Unit, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Peter Reiss
- Stichting HIV Monitoring, Amsterdam, Netherlands.,Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
| | - Christophe Fraser
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, Poizot-Martin I, Pugliese P, Rey D, Cabié A, Chirouze C, Drobacheff-Thiébaut C, Foltzer A, Bouiller K, Hustache-Mathieu L, Lepiller Q, Bozon F, Babre O, Brunel AS, Muret P, Chevalier E, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Aumeran C, Baud O, Corbin V, Goncalvez E, Mirand A, brebion A, Henquell C, Lamaury I, Fabre I, Curlier E, Ouissa R, Herrmann-Storck C, Tressieres B, Receveur MC, Boulard F, Daniel C, Clavel C, Roger PM, Markowicz S, Chellum Rungen N, Merrien D, Perré P, Guimard T, Bollangier O, Leautez S, Morrier M, Laine L, Boucher D, Point P, Cotte L, Ader F, Becker A, Boibieux A, Brochier C, Brunel-Dalmas F, Cannesson O, Chiarello P, Chidiac C, Degroodt S, Ferry T, Godinot M, Livrozet JM, Makhloufi D, Miailhes P, Perpoint T, Perry M, Pouderoux C, Roux S, Triffault-Fillit C, Valour F, Charre C, Icard V, Tardy JC, Trabaud MA, Ravaux I, Ménard A, Belkhir AY, Colson P, Dhiver C, Madrid A, Martin-Degioanni M, Meddeb L, Mokhtari M, Motte A, Raoux A, Toméi C, Tissot-Dupont H, Poizot-Martin I, Brégigeon S, Zaegel-Faucher O, Obry-Roguet V, Laroche H, Orticoni M, Soavi MJ, Ressiot E, Ducassou MJ, Jaquet I, Galie S, Colson H, Ritleng AS, Ivanova A, Debreux C, Lions C, Rojas-Rojas T, Cabié A, Abel S, Bavay J, Bigeard B, Cabras O, Cuzin L, Dupin de Majoubert R, Fagour L, Guitteaud K, Marquise A, Najioullah F, Pierre-François S, Pasquier J, Richard P, Rome K, Turmel JM, Varache C, Atoui N, Bistoquet M, Delaporte E, Le Moing V, Makinson A, Meftah N, Merle de Boever C, Montes B, Montoya Ferrer A, Tuaillon E, Reynes J, Lefèvre B, Jeanmaire E, Hénard S, Frentiu E, Charmillon A, Legoff A, Tissot N, André M, Boyer L, Bouillon MP, Delestan M, Goehringer F, Bevilacqua S, Rabaud C, May T, Raffi F, Allavena C, Aubry O, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet-Cartier C, Deschanvres C, Gaborit BJ, Grégoire A, Grégoire M, Grossi O, Guéry R, Jovelin T, Lefebvre M, Le Turnier P, Lecomte R, Morineau P, Reliquet V, Sécher S, Cavellec M, Paredes E, Soria A, Ferré V, André-Garnier E, Rodallec A, Pugliese P, Breaud S, Ceppi C, Chirio D, Cua E, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Garraffo R, Michelangeli C, Mondain V, Naqvi A, Oran N, Perbost I, Carles M, Klotz C, Maka A, Pradier C, Prouvost-Keller B, Risso K, Rio V, Rosenthal E, Touitou I, Wehrlen-Pugliese S, Zouzou G, Hocqueloux L, Prazuck T, Gubavu C, Sève A, Giaché S, Rzepecki V, Colin M, Boulard C, Thomas G, Cheret A, Goujard C, Quertainmont Y, Teicher E, Lerolle N, Jaureguiberry S, Colarino R, Deradji O, Castro A, Barrail-Tran A, Yazdanpanah Y, Landman R, Joly V, Ghosn J, Rioux C, Lariven S, Gervais A, Lescure FX, Matheron S, Louni F, Julia Z, Le GAC S, Charpentier C, Descamps D, Peytavin G, Duvivier C, Aguilar C, Alby-Laurent F, Amazzough K, Benabdelmoumen G, Bossi P, Cessot G, Charlier C, Consigny PH, Jidar K, Lafont E, Lanternier F, Leporrier J, Lortholary O, Louisin C, Lourenco J, Parize P, Pilmis B, Rouzaud C, Touam F, Valantin MA, Tubiana R, Agher R, Seang S, Schneider L, PaLich R, Blanc C, Katlama C, Bani-Sadr F, Berger JL, N’Guyen Y, Lambert D, Kmiec I, Hentzien M, Brunet A, Romaru J, Marty H, Brodard V, Arvieux C, Tattevin P, Revest M, Souala F, Baldeyrou M, Patrat-Delon S, Chapplain JM, Benezit F, Dupont M, Poinot M, Maillard A, Pronier C, Lemaitre F, Morlat C, Poisson-Vannier M, Jovelin T, Sinteff JP, Gagneux-Brunon A, Botelho-Nevers E, Frésard A, Ronat V, Lucht F, Rey D, Fischer P, Partisani M, Cheneau C, Priester M, Mélounou C, Bernard-Henry C, de Mautort E, Fafi-Kremer S, Delobel P, Alvarez M, Biezunski N, Debard A, Delpierre C, Gaube G, Lansalot P, Lelièvre L, Marcel M, Martin-Blondel G, Piffaut M, Porte L, Saune K, Robineau O, Ajana F, Aïssi E, Alcaraz I, Alidjinou E, Baclet V, Bocket L, Boucher A, Digumber M, Huleux T, Lafon-Desmurs B, Meybeck A, Pradier M, Tetart M, Thill P, Viget N, Valette M. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018. Clin Infect Dis 2021; 73:e3266-e3274. [DOI: 10.1093/cid/ciaa1940] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 01/01/2021] [Indexed: 01/15/2023] Open
Abstract
Abstract
Background
The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency virus (HIV)-HCV–coinfected patients are deemed a priority population for HCV elimination, while a rise in recently acquired HCV infections in men who have sex with men (MSM) has been described. We describe the variations in HIV-HCV epidemiology in the French Dat’AIDS cohort.
Methods
This was a retrospective analysis of a prospective cohort of persons living with HIV (PLWH) from 2012 to 2018. We determined HCV prevalence, HCV incidence, proportion of viremic patients, treatment uptake, and mortality rate in the full cohort and by HIV risk factors.
Results
From 2012 to 2018, 50 861 PLWH with a known HCV status were followed up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100 person-years to 1.25/100 person-years in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%). In MSM, treatment at the acute phase represented 30.0% of treatments in 2018.
Conclusions
A major shift in HCV epidemiology was observed in PLWH in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM.
Clinical Trials Registration. NCT02898987.
Collapse
Affiliation(s)
- Laurent Cotte
- Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Lyon, France
| | - Laurent Hocqueloux
- Department of Infectious Diseases, Centre Hospitalier Régional d’Orléans – La Source, Orléans, France
| | - Maeva Lefebvre
- Department of Infectious Diseases, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes; Centre d’Investigation Clinique (CIC) 1413, INSERM, Nantes, France
| | - Pierre Pradat
- Center for Clinical Research, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - Firouze Bani-Sadr
- Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debré Hospital, University Hospital, Reims, France
| | - Thomas Huleux
- Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France
| | - Isabelle Poizot-Martin
- Immuno-Hematology Clinic, Assistance Publique–Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, Aix-MarseilleUniversity–Inserm–Institut de Recherche pour le Développement (IRD), Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France
| | - Pascal Pugliese
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l’Archet, Nice, France
| | - David Rey
- HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg
| | - André Cabié
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Martinique, Fort de France, Université des Antilles EA4537, Fort de France, INSERM CIC1424, Fort-de-France, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Bal A, Casalegno JS, Melenotte C, Daviet F, Ninove L, Edouard S, Morfin F, Valette M, De Lamballerie X, Lina B, Papazian L, Nougairède A, Hraiech S. Influenza-induced acute respiratory distress syndrome during the 2010-2016 seasons: bacterial co-infections and outcomes by virus type and subtype. Clin Microbiol Infect 2020; 26:947.e1-947.e4. [PMID: 32205296 DOI: 10.1016/j.cmi.2020.03.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Revised: 02/22/2020] [Accepted: 03/07/2020] [Indexed: 01/07/2023]
Abstract
OBJECTIVES We aimed to describe bacterial co-infections and acute respiratory distress (ARDS) outcomes according to influenza type and subtype. METHODS A retrospective observational study was conducted from 2012 to 2016 in patients admitted to the respiratory intensive care unit (ICU) of Marseille university hospital for influenza-induced ARDS. Microbiological investigations, including multiplex molecular respiratory panel testing and conventional bacteriological cultures, were performed as part of the routine ICU care on the bronchoalveloar lavage collected at admission. Bacterial co-infections, ICU mortality and respiratory function were investigated according to virus type and subtype. RESULTS Among the 45 ARDS patients included, A(H1N1)pdm09 was the most frequent influenza virus identified (28/45 A(H1N1)pdm09, eight out of 45 A(H3N2) and nine out of 45 influenza B). Bacterial co-infections involving a total of 23 bacteria were diagnosed in 16/45 patients (36%). A(H1N1)pdm09 patients presented fewer bacterial co-infections (17.9% vs. 50.0% for A(H3N2) patients and 77.8% for B patients; p < 0.01). Overall, mortality at 90 days post admission was 33.3% (15/45), and there was no significant difference between influenza type and subtype. The need for extracorporeal membrane oxygenation was more frequent for A(H1N1)pdm2009 (20/28, 71.4%) and B patients (7/9, 77.8%) than the A(H3N2) subtype (1/8, 12.5%; p < 0.01). A(H1N1)pdm09-ARDS patients were associated with fewer ventilation-free days at day 28 (median (IQR): 0 (0-8) days) compared with other influenza-ARDS patients (15 (0-25) days, p < 0.05). DISCUSSION In a population of influenza-induced ARDS, A(H1N1)pdm09 was associated with fewer bacterial co-infections but poorer respiratory outcomes. These data underline the major role of A(H1N1)pdm09 subtype on influenza disease severity.
Collapse
Affiliation(s)
- A Bal
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - J S Casalegno
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - C Melenotte
- Aix Marseille University, IRD, AP-HM, MEPHI, IHU Méditerranée Infection, Marseille, France
| | - F Daviet
- Service de Médecine Intensive - Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS - Centre for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, France
| | - L Ninove
- Unité des Virus Emergents (UVE: Aix- Marseille Univ., IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France
| | - S Edouard
- Aix Marseille University, IRD, AP-HM, MEPHI, IHU Méditerranée Infection, Marseille, France
| | - F Morfin
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - M Valette
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - X De Lamballerie
- Unité des Virus Emergents (UVE: Aix- Marseille Univ., IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France
| | - B Lina
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - L Papazian
- Service de Médecine Intensive - Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS - Centre for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, France
| | - A Nougairède
- Unité des Virus Emergents (UVE: Aix- Marseille Univ., IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France
| | - S Hraiech
- Service de Médecine Intensive - Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS - Centre for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, France.
| |
Collapse
|
5
|
Bal A, Destras G, Gaymard A, Bouscambert-Duchamp M, Valette M, Escuret V, Frobert E, Billaud G, Trouillet-Assant S, Cheynet V, Brengel-Pesce K, Morfin F, Lina B, Josset L. Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del). Clin Microbiol Infect 2020; 26:960-962. [PMID: 32234449 PMCID: PMC7142683 DOI: 10.1016/j.cmi.2020.03.020] [Citation(s) in RCA: 48] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 03/21/2020] [Indexed: 11/30/2022]
Affiliation(s)
- A Bal
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France; Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - G Destras
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - A Gaymard
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - M Bouscambert-Duchamp
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - M Valette
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - V Escuret
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - E Frobert
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - G Billaud
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - S Trouillet-Assant
- Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France; Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - V Cheynet
- Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - K Brengel-Pesce
- Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - F Morfin
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - B Lina
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - L Josset
- Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.
| |
Collapse
|
6
|
Moustafa F, Robert A, Debbabi H, Borel M, Valette M, Perrier C, Raconnat J, Schmidt J. Risk stratification of emergency pulmonary embolism according to the s-PESI score. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
7
|
Deconinck L, Robineau O, Valette M, Choisy P, Bocket L, Meybeck A, Ajana F. Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study. BMC Infect Dis 2019; 19:467. [PMID: 31126239 PMCID: PMC6534926 DOI: 10.1186/s12879-019-4047-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2018] [Accepted: 04/29/2019] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND The circumstances of prescription of tropism tests clinically relevant in treatment-experienced patients are unclear. METHODS We performed a monocentric retrospective analysis of all tropism tests performed between 2006 and 2015 in HIV-infected patients on antiretroviral therapy (ART) without MVC. The motivation of tropism determination was collected. Factors associated with MVC prescription were determined using logistic regression analysis. RESULTS Five hundred sixty-three tests were performed in experienced patients not receiving MVC. Reasons for tropism performance were: virological failure (44%), side effects or drug-interactions (37%), simplification or sparing strategies (11%), immunological failure (5%), and improvement of neurological diffusion (3%). MVC was prescribed in 110 cases (20%), though 366 tests (65%) revealed a tropism CCR5. MVC was more often prescribed before 2011 (OR 3.65, 95% CI 2.17-6.13) and in patients with multiple previous ART regimens (less than 4 ART regimens compare to more than 10 ART regimens (OR 0.34, 95% CI 0.15-0.74)). CONCLUSIONS In experienced patients not receiving MVC, tropism test prescription should be restricted to patients with virological failure and limited therapeutic options such as patients already treated with a wide range of ART regimens.
Collapse
Affiliation(s)
- Laurène Deconinck
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France.
| | - Olivier Robineau
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
| | - Michel Valette
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
| | - Philippe Choisy
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
| | - Laurence Bocket
- Virology Department, Lille University Hospital, Lille, France
| | - Agnes Meybeck
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
| | - Faiza Ajana
- Infectious Diseases Department, Tourcoing Hospital, Tourcoing, France
| |
Collapse
|
8
|
Tetart M, Meybeck A, Assaf A, Valette M, Choisy P, Blondiaux N, Senneville E. Factors of loss to follow-up during tuberculosis treatment in a low-incidence region. Med Mal Infect 2019; 50:28-35. [PMID: 30890281 DOI: 10.1016/j.medmal.2019.02.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 03/03/2018] [Accepted: 02/22/2019] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The proportion of successfully treated tuberculosis (TB) patients remains below the WHO target in France, because of a high proportion of loss to follow-up. We aimed to identify factors associated with loss to follow-up in northern France, a low-incidence area. METHODS Between 1997 and 2017, all consecutive patients diagnosed with TB at the Tourcoing Hospital, except those infected with multidrug-resistant or extensively drug-resistant strains, were included in a retrospective cohort study. A logistic regression analysis was performed to determine factors associated with loss to follow-up. RESULTS One hundred and ninety patients were included. Previous TB treatment was reported in 32 patients (17%), extrapulmonary TB in 107 (56%), and HIV infection in 44 (23%). The proportion of loss to follow-up was 15%. In multivariate analysis, the risk of loss to follow-up decreased in case of first TB treatment (OR 0.36; 95% CI: 0.14-0.92, P=0.03) and increased in non-HIV-infected patients (OR 7.67; 95% CI: 1.00-59.0, p=0.05). Support for compliance was more frequent in HIV-infected patients (23% vs. 7%, p=0.005). CONCLUSION The proportion of loss to follow-up was high. HIV infection was associated with a lower risk of loss to follow-up, likely to be due to more frequent support for compliance.
Collapse
Affiliation(s)
- M Tetart
- Service des maladies infectieuses, centre hospitalier Dron, 135, avenue du Président-Coty, 59200 Tourcoing, France
| | - A Meybeck
- Service des maladies infectieuses, centre hospitalier Dron, 135, avenue du Président-Coty, 59200 Tourcoing, France.
| | - A Assaf
- Service des maladies infectieuses, centre hospitalier Dron, 135, avenue du Président-Coty, 59200 Tourcoing, France
| | - M Valette
- Service des maladies infectieuses, centre hospitalier Dron, 135, avenue du Président-Coty, 59200 Tourcoing, France
| | - P Choisy
- Service des maladies infectieuses, centre hospitalier Dron, 135, avenue du Président-Coty, 59200 Tourcoing, France
| | - N Blondiaux
- Laboratoire de microbiologie, centre hospitalier Dron, 59200 Tourcoing, France
| | - E Senneville
- Service des maladies infectieuses, centre hospitalier Dron, 135, avenue du Président-Coty, 59200 Tourcoing, France
| |
Collapse
|
9
|
Joseph C, Robineau O, Titecat M, Putman S, Blondiaux N, Loiez C, Valette M, Schmit JL, Beltrand E, Dézeque H, Nguyen S, Migaud H, Senneville E. Daptomycin versus Vancomycin as Post-Operative Empirical Antibiotic Treatment for Prosthetic Joint Infections: A Case-Control Study. J Bone Jt Infect 2019; 4:72-75. [PMID: 31011511 PMCID: PMC6470651 DOI: 10.7150/jbji.22118] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Accepted: 06/16/2018] [Indexed: 12/31/2022] Open
Abstract
Purpose: To compare safety and efficacy of Vancomycin (Van) versus Daptomycin (Dap) as post-operative empirical antibiotic treatment (PEAT) in patients with periprosthetic joint infections (PJIs). Methods: Medical charts of patients treated empirically with Van or Dap in the post-operative period of total hip/knee prosthesis septic revision until the results of intra-operative culture were reviewed. Cefotaxime, cefepime or aztreonam were used in combination with Dap or Van. Results: Twenty Dap patients were matched with 20 other Van patients according to the age and type of prosthesis. The ASA score and the distribution of the pathogens was similar in the two groups especially regarding the number of methicillin-resistant staphylococci. The mean duration of the PEAT was 6.07 ± 0.85 days. A total of 17 episodes of adverse events (AE) in 10 patients (25%) were recorded during the PEAT which led to discontinue the treatment in 5 patients, all of them treated with Van (P=0.02). At the end of a mean post-treatment follow-up of 618 +/- 219 days, 36 patients remained in remission of infection; 2 patients failed in each group. Conclusions: Our observations suggest that PEAT with Van for septic revision of PJIs is associated with a higher discontinuation rate due to AE but with a similar outcome than it is with Dap.
Collapse
Affiliation(s)
- C Joseph
- Infectious Diseases Department, University Hospital of Amiens, France
| | - O Robineau
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, France.,Faculty of Medicine of Lille, Lille University 2
| | - M Titecat
- Faculty of Medicine of Lille, Lille University 2.,Laboratory of Microbiology, University Hospital of Lille, France
| | - S Putman
- Orthopaedic Surgery Unit, University Hospital of Lille, France
| | - N Blondiaux
- Laboratory of Microbiology, Gustave Dron Hospital of Tourcoing, France
| | - C Loiez
- Laboratory of Microbiology, University Hospital of Lille, France
| | - M Valette
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, France
| | - J L Schmit
- Infectious Diseases Department, University Hospital of Amiens, France
| | - E Beltrand
- Orthopedic Surgery Unit, Gustave Dron Hospital, France
| | - H Dézeque
- Orthopaedic Surgery Unit, University Hospital of Lille, France
| | | | - H Migaud
- Faculty of Medicine of Lille, Lille University 2.,Orthopaedic Surgery Unit, University Hospital of Lille, France
| | - E Senneville
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, France.,Faculty of Medicine of Lille, Lille University 2.,Orthopaedic Surgery Unit, University Hospital of Lille, France
| |
Collapse
|
10
|
Souty C, Masse S, Valette M, Behillil S, Bonmarin I, Pino C, Turbelin C, Capai L, Vilcu AM, Lina B, van der Werf S, Blanchon T, Falchi A, Hanslik T. Baseline characteristics and clinical symptoms related to respiratory viruses identified among patients presenting with influenza-like illness in primary care. Clin Microbiol Infect 2019; 25:1147-1153. [PMID: 30703528 PMCID: PMC7172742 DOI: 10.1016/j.cmi.2019.01.014] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 01/07/2019] [Accepted: 01/20/2019] [Indexed: 11/28/2022]
Abstract
Objectives We aimed to identify patients' clinical characteristics associated with respiratory viruses identified among patients presenting with influenza-like illness (ILI). Methods A sample of patients of all ages presenting with ILI was included by physicians of the French Sentinelles network during two seasons (2015/16 and 2016/17). Nasopharyngeal samples were tested for the presence of influenza virus (IV), respiratory syncytial virus (RSV), human rhinovirus (HRV) and human metapneumovirus (HMPV). Patients' characteristics associated with each of the four virus classes were studied using multivariate logistic regressions. Results A total of 5859 individuals were included in the study: 48.0% tested positive for IV, 7.9% for HRV, 7.5% for RSV and 4.1% for HMPV. Cough was associated with IV (OR 2.14, 95% CI 1.81–2.52) RSV (OR 2.52, 95% CI 1.75–3.74) and HMPV detection (OR 2.15, 95% CI 1.40–3.45). Rhinorrhoea was associated mainly with HRV detection (OR 1.75, 95% CI 1.34–2.32). Headache was associated with IV detection (OR 1.75, 95% CI 1.34–2.32), whereas absence of headache was associated with RSV and HMPV detection. Dyspnoea was associated with RSV detection (OR 2.33, 95% CI 1.73–3.12) and absence of dyspnoea with IV detection. Conjunctivitis was associated with IV detection (OR 1.27, 95% CI 1.08–1.50). Some associations were observed only in children: dyspnoea and cough with RSV detection (age <5 years), conjunctivitis with IV detection (age <15 years). Period of onset of symptoms differed among aetiological diagnoses. Seasonal influenza vaccination decreased the risk of IV detection (OR, 0.67, 95% CI 0.51–0.86). Conclusions This study allowed the identification of symptoms associated with several viral aetiologies in patients with ILI. A proper knowledge and understanding of these clinical signs may improve the medical management of patients.
Collapse
Affiliation(s)
- C Souty
- Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé publique, Paris, France.
| | - S Masse
- Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé publique, Paris, France; EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France
| | - M Valette
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Centre National de Référence des virus respiratoires (dont la grippe), Centre de Biologie et de Pathologie Nord, Groupement Hospitalier Nord, Lyon, France; Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, France
| | - S Behillil
- Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Paris, France; Institut Pasteur, Centre Coordonnateur du Centre National de Référence des virus des infections respiratoires (dont la grippe), Paris, France; UMR CNRS 3569, 75015, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Unité de Génétique Moléculaire des Virus à ARN, Paris, France
| | - I Bonmarin
- Santé publique France, French National Public Health Agency, Saint-Maurice, France
| | - C Pino
- Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé publique, Paris, France
| | - C Turbelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé publique, Paris, France
| | - L Capai
- Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé publique, Paris, France; EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France
| | - A M Vilcu
- Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé publique, Paris, France
| | - B Lina
- Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Centre National de Référence des virus respiratoires (dont la grippe), Centre de Biologie et de Pathologie Nord, Groupement Hospitalier Nord, Lyon, France; Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, France
| | - S van der Werf
- Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Paris, France; Institut Pasteur, Centre Coordonnateur du Centre National de Référence des virus des infections respiratoires (dont la grippe), Paris, France; UMR CNRS 3569, 75015, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Unité de Génétique Moléculaire des Virus à ARN, Paris, France
| | - T Blanchon
- Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé publique, Paris, France
| | - A Falchi
- EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France
| | - T Hanslik
- Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé publique, Paris, France; Université de Versailles Saint-Quentin-en-Yvelines, UVSQ, UFR de Médecine, Versailles, France; Assistance Publique - Hôpitaux de Paris APHP, Hôpital Ambroise Paré, Service de Médecine Interne, Boulogne Billancourt, France
| |
Collapse
|
11
|
Pasquet A, Robineau O, Valette M, D’Elia PV, Vandamme S, Leroy O, Lafon-Desmurs B, Senneville E. 2141. Characteristics and Prognosis of Patients with a Prosthetic Vascular Graft Infection (PVGI): A Prospective Cohort of 200 patients. Open Forum Infect Dis 2018. [PMCID: PMC6252800 DOI: 10.1093/ofid/ofy210.1797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Background The aim of the present study was to describe the characteristics and prognosis of patients admitted for a PVGI and to assess the factors associated with the death of these patients. Methods All consecutive patients admitted in our department between January 1, 2000 and January 1, 2018 for a PVGI were enrolled in the present prospective cohort study. PVGIs were divided into extracavitary (femoro-femoral, femoro-popliteal and axillo-femoral) and cavitary (aorto-iliac, aorto-femoral, ilio-femoral, aortic); into “early” infection (<4 months) and late. Patients’ baseline characteristics and their follow-up were described, and factors associated with death were assessed by using a logistic multivariate regression model. Results Overall, 200 patients were included during this period. The median age of patients was 69 years [IQR: 61–78], mainly of men (86%). One hundred and sixteen patients had an intracavitary PVGI (58%). Enterobacteriaceae and MSSA were the most frequent pathogens (n = 60 and 59), followed by coagulase negative staphylococci (n = 30), Streptococcus (n = 26) and enterococcus (n = 25). Surgery with replacement of the infected prosthesis was performed in 102 patients (53%). Culture of material samples taken during surgery were plurimicrobial in 67 patients (34%). After surgery, the median follow-up of patients was 7.5 months [IQR: 2–19] during which 30 presented a failure (15%) and 85 patients died, 41 due to the PVGI (21%). Factors independently associated with death in multivariate analysis were: to be over 70 years old (OR = 8.2; P < 0.01), to stay in ICU for more than 6 days (OR = 5.9; P = 0.01) and to have an intracavitary PVGI (OR = 9.0; P = 0.02). Antibiotic therapy regimen combining rifampicin to another antibiotic was associated with a decreased mortality (OR = 0.11; P < 0.01). Conclusion Our results suggest that the prognostic of patients admitted for PVGI depends on the site of infection and the occurrence of a shock after the admission. We found a better prognosis for patients with an extracavitary PVGI, without sepsis. Finally, PVGI treated with an antibiotic combination including rifampicin had a better outcome. Disclosures All authors: No reported disclosures.
Collapse
|
12
|
Coehlo A, Robineau O, Titecat M, Putman S, Blondiaux N, Valette M, Beltrand E, Migaud H, Senneville E. 315. Oral Vs. Intravenous Antibiotic Treatment for Gram-Positive Prosthetic Joint Infections: A Retrospective Study. Open Forum Infect Dis 2018. [PMCID: PMC6255525 DOI: 10.1093/ofid/ofy210.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Background Intravenous antibiotic infusion is the current standard for prosthetic joint infections (PJIs) management. antibiotic used for PJIs have a good oral bioavailability, especially rifampicin, suggesting that oral and IV route could be as efficient. Our aim was to compare the outcome of PJIs treated by oral antibiotics to those treated intravenously. Methods a retrospective survey was done in two reference centers between 2014 and 2016 and included all patients presenting Gram-positive PJIs. In these centers, patients suffering from Gram-positive PJIs could receive IV or early oral antibiotics regimen (started the day final antibiogram were received). First, we compared these two groups in terms of demographic and infection characteristics. Then, the outcome, judged by the percentage of patient with a relapse or a new infection on the same site during the follow-up, was compared. Results Within this period, 87 patients were treated for Gram-positive BJIs, 51 (59%) received early oral therapy and 36 were treated intravenously. Median age was 65 [IQR = 56–75], 50 (57%) were female. Overall, 18 cases suffered from polymicrobial BJIs containing at least one staphylococci. S. aureus was found in 30 (34%) cases and 7 (8%) strains were resistant to ampicillin. The median time of follow-up was 467 days [IQR=218–729]. The median time of treatment was 60 days [IQR=44–84]. When comparing the oral therapy group and IV group, we did not find any difference in terms of comorbidities, infection characteristics, type of surgery and infection severity. In the oral therapy group, the oral antibiotic regimen was started before day 7 following surgery for 33 (76%) individuals and before day 10 for 44 (86%). Treatment failures were observed in 9/36 (25%) and 12/51(23.5%) (P = 1) in IV and oral therapy group, respectively. Conclusion Oral antibiotic treatment seems to be as efficient as an intravenous regimen to treat prosthetic Gram-positive prosthetic joint infections. Disclosures All authors: No reported disclosures.
Collapse
|
13
|
Bal A, Pichon M, Picard C, Casalegno JS, Valette M, Schuffenecker I, Billard L, Vallet S, Vilchez G, Cheynet V, Oriol G, Trouillet-Assant S, Gillet Y, Lina B, Brengel-Pesce K, Morfin F, Josset L. Quality control implementation for universal characterization of DNA and RNA viruses in clinical respiratory samples using single metagenomic next-generation sequencing workflow. BMC Infect Dis 2018; 18:537. [PMID: 30373528 PMCID: PMC6206636 DOI: 10.1186/s12879-018-3446-5] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Accepted: 10/16/2018] [Indexed: 12/20/2022] Open
Abstract
Background In recent years, metagenomic Next-Generation Sequencing (mNGS) has increasingly been used for an accurate assumption-free virological diagnosis. However, the systematic workflow evaluation on clinical respiratory samples and implementation of quality controls (QCs) is still lacking. Methods A total of 3 QCs were implemented and processed through the whole mNGS workflow: a no-template-control to evaluate contamination issues during the process; an internal and an external QC to check the integrity of the reagents, equipment, the presence of inhibitors, and to allow the validation of results for each sample. The workflow was then evaluated on 37 clinical respiratory samples from patients with acute respiratory infections previously tested for a broad panel of viruses using semi-quantitative real-time PCR assays (28 positive samples including 6 multiple viral infections; 9 negative samples). Selected specimens included nasopharyngeal swabs (n = 20), aspirates (n = 10), or sputums (n = 7). Results The optimal spiking level of the internal QC was first determined in order to be sufficiently detected without overconsumption of sequencing reads. According to QC validation criteria, mNGS results were validated for 34/37 selected samples. For valid samples, viral genotypes were accurately determined for 36/36 viruses detected with PCR (viral genome coverage ranged from 0.6 to 100%, median = 67.7%). This mNGS workflow allowed the detection of DNA and RNA viruses up to a semi-quantitative PCR Ct value of 36. The six multiple viral infections involving 2 to 4 viruses were also fully characterized. A strong correlation between results of mNGS and real-time PCR was obtained for each type of viral genome (R2 ranged from 0.72 for linear single-stranded (ss) RNA viruses to 0.98 for linear ssDNA viruses). Conclusions Although the potential of mNGS technology is very promising, further evaluation studies are urgently needed for its routine clinical use within a reasonable timeframe. The approach described herein is crucial to bring standardization and to ensure the quality of the generated sequences in clinical setting. We provide an easy-to-use single protocol successfully evaluated for the characterization of a broad and representative panel of DNA and RNA respiratory viruses in various types of clinical samples. Electronic supplementary material The online version of this article (10.1186/s12879-018-3446-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- A Bal
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.,Univ Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.,Centre National de Reference des virus respiratoires France Sud, Hospices Civils de Lyon, 103 Grande-Rue de la Croix Rousse, 69317, Lyon, France.,Laboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - M Pichon
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.,Univ Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.,Centre National de Reference des virus respiratoires France Sud, Hospices Civils de Lyon, 103 Grande-Rue de la Croix Rousse, 69317, Lyon, France
| | - C Picard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,CIRI Inserm U1111, CNRS 5308, ENS, UCBL, Faculté de Médecine Lyon Est, Université de Lyon, Lyon, France
| | - J S Casalegno
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.,Univ Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.,Centre National de Reference des virus respiratoires France Sud, Hospices Civils de Lyon, 103 Grande-Rue de la Croix Rousse, 69317, Lyon, France
| | - M Valette
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.,Univ Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.,Centre National de Reference des virus respiratoires France Sud, Hospices Civils de Lyon, 103 Grande-Rue de la Croix Rousse, 69317, Lyon, France
| | - I Schuffenecker
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France
| | - L Billard
- INSERM UMR1078 "Génétique, Génomique Fonctionnelle et Biotechnologies", Axe Microbiota, Univ Brest, Brest, France
| | - S Vallet
- INSERM UMR1078 "Génétique, Génomique Fonctionnelle et Biotechnologies", Axe Microbiota, Univ Brest, Brest, France.,Département de Bactériologie-Virologie, Hygiène et Parasitologie-Mycologie, Pôle de Biologie-Pathologie, Centre Hospitalier Régional et Universitaire de Brest, Hôpital de la Cavale Blanche, Brest, France
| | - G Vilchez
- Laboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - V Cheynet
- Laboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - G Oriol
- Laboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - S Trouillet-Assant
- Laboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - Y Gillet
- Hospices Civils de Lyon, Urgences pédiatriques, Hôpital Femme Mère Enfant, Bron, France
| | - B Lina
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.,Univ Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.,Centre National de Reference des virus respiratoires France Sud, Hospices Civils de Lyon, 103 Grande-Rue de la Croix Rousse, 69317, Lyon, France
| | - K Brengel-Pesce
- Laboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - F Morfin
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.,Univ Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.,Centre National de Reference des virus respiratoires France Sud, Hospices Civils de Lyon, 103 Grande-Rue de la Croix Rousse, 69317, Lyon, France
| | - L Josset
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France. .,Univ Lyon, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France. .,Centre National de Reference des virus respiratoires France Sud, Hospices Civils de Lyon, 103 Grande-Rue de la Croix Rousse, 69317, Lyon, France.
| |
Collapse
|
14
|
Boucher A, Meybeck A, Alidjinou K, Huleux T, Viget N, Baclet V, Valette M, Alcaraz I, Sauser E, Bocket L, Faiza A. Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France. Sex Transm Infect 2018; 95:75-77. [PMID: 29886426 DOI: 10.1136/sextrans-2017-053395] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 04/26/2018] [Accepted: 05/13/2018] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVES Since February 2017, an increase of acute hepatitis A (AHA) cases has been notified in North of France. We aimed to report clinical and virological features of 49 cases treated in three hospitals in Lille European Metropolis (LEM). METHODS All adult patients treated for AHA in 3 LEM hospitals between 20 February and 5 July 2017 were included. Demographic characteristics, exposure risk factors to hepatitis A virus (HAV), AHA manifestations and concomitant sexually transmitted infections (STI) were retrospectively recorded. RESULTS Forty-nine cases of AHA were diagnosed among which 34 (69%) were hospitalised. Severe AHA occurred in 7 (14%) patients. The median age of cases was 36 years. All cases except 1 were men and 32 (65%) were identified as men having sex with men (MSM). Eleven (23%) patients were HIV-infected, 5 were under HIV pre-exposure prophylaxis (PrEP), 6 had a history of HIV postexposure prophylaxis and 19 had a history of at least one STI. Only three patients had received HAV vaccine. Proportion of patients tested for syphilis, chlamydial and gonococcal infections was 75% (18/24) in those seen by sexual health specialists and 21% (6/29) in those seen by other specialists. At least one concomitant STI was diagnosed in 13 out of 24 tested patients (54%). RT-PCR sequencing was available for 38 cases and confirmed co-circulation of 3 different strains of subgenotype IA (VRD 521 2016: n=24, RIVM-HAV16-090: n=13, V16-25801: n=1), already identified in several European countries. CONCLUSIONS We are facing an outbreak of AHA among MSM in the North of France with a high rate of hospitalisation. Analysis of cases highlighted missed opportunities of vaccination and lack of concomitant STI screening. Awareness among healthcare providers and MSM should be increased and HAV vaccination promoted.
Collapse
Affiliation(s)
- Anne Boucher
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - Agnes Meybeck
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | | | - Thomas Huleux
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - Nathalie Viget
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - Veronique Baclet
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - Michel Valette
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - Isabelle Alcaraz
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | | | | | - Ajana Faiza
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| |
Collapse
|
15
|
Boucher A, Robineau O, Meybeck A, Baclet V, Huleux T, Valette M, Viget N, Alcaraz I, Senneville E, Ajana F. Évaluation de l’immunogénicité du vaccin contre l’hépatite A chez les patients infectés par le VIH : état des lieux avant et après l’ère des nouveaux antirétroviraux. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Robineau O, Huleux T, Meybeck A, Boucher A, Valette M, Baclet V, Aissi E, Alcaraz I, Senneville E. Immunisation contre l’hépatite A autour d’une épidémie chez les hommes ayant des rapports sexuels avec des hommes (HSH) suivis pour une infection VIH ou dans le cadre de la PreP : impact d’une campagne de vaccination en période de contingentement des vaccins. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Pasquet A, Robinneau O, Valette M, D’ellia P, Vandamme S, Lafon-Desmurs B, Leroy O, Senneville E. Caractéristiques et pronostic d’une cohorte de patients hospitalisés pour une infection de prothèse vasculaire (IPV) 2000 et 2018. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
18
|
Janin H, Vilain Parce A, Kaminski H, Valette M, Cazanave C. Épidémie de grippe 2015–2016 : caractère tardif, gravité clinique et émergence du virus B Victoria. Med Mal Infect 2018; 48:73-74. [DOI: 10.1016/j.medmal.2017.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 08/26/2017] [Accepted: 09/12/2017] [Indexed: 10/18/2022]
|
19
|
Berthol N, Robineau O, Boucher A, Blondiaux N, Beltrand E, Valette M, Cazaubiel M, Nguyen S, Senneville E. Two-Step Sequential Approach for Concomitant Skin and Soft Tissue Infection and Osteomyelitis Complicating the Diabetic Foot. Diabetes Care 2017; 40:e170-e171. [PMID: 28993420 DOI: 10.2337/dc17-1471] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 08/28/2017] [Indexed: 02/03/2023]
Affiliation(s)
- Naïma Berthol
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| | - Olivier Robineau
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France.,Faculty of Medicine, Lille University 2, Lille, France
| | - Anne Boucher
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France.,Faculty of Medicine, Lille University 2, Lille, France
| | - Nicolas Blondiaux
- Laboratory of Microbiology, Gustave Dron Hospital, Tourcoing, France
| | - Eric Beltrand
- Orthopaedic Surgery Unit, Gustave Dron Hospital, Tourcoing, France
| | - Michel Valette
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| | - Marie Cazaubiel
- Diabetology Department, Gustave Dron Hospital, Tourcoing, France
| | | | - Eric Senneville
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France .,Faculty of Medicine, Lille University 2, Lille, France
| |
Collapse
|
20
|
Jalonen R, Valette M, Boshier D, Duminil J, Thomas E. Forest and landscape restoration severely constrained by a lack of attention to the quantity and quality of tree seed: Insights from a global survey. Conserv Lett 2017. [DOI: 10.1111/conl.12424] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
| | - Michel Valette
- Department of Biology and Ecology; University of Montpellier II; France
| | - David Boshier
- Department of Plant Sciences; University of Oxford; United Kingdom
| | - Jérôme Duminil
- Bioversity International; Cameroon
- Institut de Recherche pour le Développement; UMR DIADE; France
| | | |
Collapse
|
21
|
Pradier M, Robineau O, Boucher A, Titecat M, Blondiaux N, Valette M, Loïez C, Beltrand E, Nguyen S, Dézeque H, Migaud H, Senneville E. Suppressive antibiotic therapy with oral tetracyclines for prosthetic joint infections: a retrospective study of 78 patients. Infection 2017; 46:39-47. [PMID: 29052797 DOI: 10.1007/s15010-017-1077-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Accepted: 10/06/2017] [Indexed: 12/20/2022]
Abstract
PURPOSE This study aimed at describing the use of oral cyclines (i.e., doxycycline and minocycline) as suppressive antibiotic therapy (SAT) in patients with periprosthetic joint infections (PJIs). METHODS Medical charts of all patients with surgical revisions for PJIs who were given cycline-based SAT because of a high failure of various origins were reviewed. Data regarding tolerability and effectiveness of cycline-based SAT were analysed. RESULTS Seventy-eight patients of mean age 64 ± 17 years received cycline-base SAT in the period from January 2006 to January 2014. PJIs involved the knee in 37 patients (47%), the hip in 35 (45%), the elbow in 4 (5%), and the shoulder in 2 (3%) and were qualified as early in 31 patients (39.7%). Staphylococcus spp. were the most common pathogens accounting for 72.1% of the total number of bacterial strains identified. All included patients had surgery which consisted in debridement and implant retention in 59 of them (75.6%). Doxycycline and minocycline were prescribed as SAT in 72 (92%) and 6 (8%) patients, respectively. Adverse events were reported in 14 patients (18%), leading to SAT discontinuation in 6 of them (8%). After a mean follow-up of 1020 ± 597 days, a total of 22 (28.2%) patients had failed including 3 cases (3.8%) with documented acquisition of tetracycline resistance in initial pathogen(s). CONCLUSIONS Our results suggest that oral cyclines used as SAT in patients treated for PJI have an acceptable tolerability and effectiveness and appear to be a reasonable option in this setting.
Collapse
Affiliation(s)
- M Pradier
- Gustave Dron Hospital, 59200, Tourcoing, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - O Robineau
- Gustave Dron Hospital, 59200, Tourcoing, France
- Faculty of Medicine of Lille University II, 59045, Lille Cedex, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - A Boucher
- Gustave Dron Hospital, 59200, Tourcoing, France
- Faculty of Medicine of Lille University II, 59045, Lille Cedex, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - M Titecat
- Faculty of Medicine of Lille University II, 59045, Lille Cedex, France
- University Hospital of Lille, 59037, Lille Cedex, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - N Blondiaux
- Gustave Dron Hospital, 59200, Tourcoing, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - M Valette
- Gustave Dron Hospital, 59200, Tourcoing, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - C Loïez
- University Hospital of Lille, 59037, Lille Cedex, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - E Beltrand
- Gustave Dron Hospital, 59200, Tourcoing, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - S Nguyen
- General Hospital of Béthune, 62660, Beuvry, France
| | - H Dézeque
- University Hospital of Lille, 59037, Lille Cedex, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - H Migaud
- Faculty of Medicine of Lille University II, 59045, Lille Cedex, France
- University Hospital of Lille, 59037, Lille Cedex, France
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France
| | - Eric Senneville
- Gustave Dron Hospital, 59200, Tourcoing, France.
- Faculty of Medicine of Lille University II, 59045, Lille Cedex, France.
- University Hospital of Lille, 59037, Lille Cedex, France.
- French National Reference Center for Complex Osteo-articular Infections (CRIOAC Lille-Tourcoing; G4 Bone and Joint Infection Study Group), Tourcoing, France.
| |
Collapse
|
22
|
Pradier M, Nguyen S, Robineau O, Titecat M, Blondiaux N, Valette M, Loïez C, Beltrand E, Dézeque H, Migaud H, Senneville E. Suppressive antibiotic therapy with oral doxycycline for Staphylococcus aureus prosthetic joint infection: a retrospective study of 39 patients. Int J Antimicrob Agents 2017; 50:447-452. [PMID: 28668689 DOI: 10.1016/j.ijantimicag.2017.04.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2016] [Revised: 04/12/2017] [Accepted: 04/27/2017] [Indexed: 10/19/2022]
Abstract
The aim of this study was to describe the use of oral doxycycline as suppressive antibiotic therapy (SAT) in patients with Staphylococcus aureus periprosthetic (hip or knee) joint infections. The medical charts of all patients with surgical revisions for S. aureus hip or knee prosthetic joint infections (PJIs) who were given doxycycline-based SAT because of a high risk of failure of various origins were reviewed. Data regarding tolerability and effectiveness of doxycycline-based SAT were analysed. A total of 39 patients (mean age 66.1 ± 16.3 years) received doxycycline-base SAT in the period from January 2006 to January 2014. PJIs involved the hip in 23 patients (59.0%) and the knee in 16 (41.0%), and were qualified as early in 15 patients (38.5%). Methicillin-resistant S. aureus (MRSA) accounted for 22% of the total number of bacterial strains identified. All patients included in the study had surgery, which consisted of debridement and implant retention in 32 (82.1%). Adverse events likely attributable to SAT were reported in six patients (15.4%), leading to discontinuation of SAT in three (7.7%). A total of 29 patients (74.4%) remained event-free and 10 (25.6%) failed, including 8 (20.5%) relapses and 2 (5.1%) superinfections. Overall, 8 of the 10 failure cases were related to a doxycycline-susceptible pathogen. These results suggest that oral doxycycline used as SAT in patients treated for S. aureus hip or knee PJIs has an acceptable tolerability and effectiveness and appears to be a reasonable option in this setting.
Collapse
Affiliation(s)
- M Pradier
- Gustave Dron Hospital, 59200 Tourcoing, France
| | - S Nguyen
- General Hospital of Béthune, 62660 Beuvry, France
| | - O Robineau
- Gustave Dron Hospital, 59200 Tourcoing, France; Faculty of Medicine, Lille University II, 59045 Lille, France
| | - M Titecat
- Faculty of Medicine, Lille University II, 59045 Lille, France; University Hospital of Lille, 59037 Lille, France
| | - N Blondiaux
- Gustave Dron Hospital, 59200 Tourcoing, France
| | - M Valette
- Gustave Dron Hospital, 59200 Tourcoing, France
| | - C Loïez
- Faculty of Medicine, Lille University II, 59045 Lille, France
| | - E Beltrand
- Gustave Dron Hospital, 59200 Tourcoing, France
| | - H Dézeque
- Faculty of Medicine, Lille University II, 59045 Lille, France
| | - H Migaud
- Faculty of Medicine, Lille University II, 59045 Lille, France; University Hospital of Lille, 59037 Lille, France
| | - E Senneville
- Gustave Dron Hospital, 59200 Tourcoing, France; Faculty of Medicine, Lille University II, 59045 Lille, France; University Hospital of Lille, 59037 Lille, France.
| |
Collapse
|
23
|
Pradat P, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L, Chidiac C, Ferry T, Ader F, Biron F, Boibieux A, Miailhes P, Perpoint T, Schlienger I, Lippmann J, Braun E, Koffi J, Longuet C, Guéripel V, Augustin-Normand C, Brochier C, Degroodt S, Pugliese P, Ceppi C, Cua E, Cottalorda J, Courjon J, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Fuzibet J, Garraffo R, Joulie A, Risso K, Mondain V, Naqvi A, Oran N, Perbost I, Pillet S, Prouvost-Keller B, Wehrlen-Pugliese S, Rosenthal E, Sausse S, Rio V, Roger P, Brégigeon S, Faucher O, Obry-Roguet V, Orticoni M, Soavi M, Geneau de Lamarlière P, Laroche H, Ressiot E, Carta M, Ducassou M, Jacquet I, Gallie S, Galinier A, Ritleng A, Ivanova A, Blanco-Betancourt C, Lions C, Debreux C, Obry-Roguet V, Poizot-Martin I, Agher R, Katlama C, Valantin M, Duvivier C, Lortholary O, Lanternier F, Charlier C, Rouzaud C, Aguilar C, Henry B, Lebeaux D, Cessot G, Gergely A, Consigny P, Touam F, Louisin C, Alvarez M, Biezunski N, Cuzin L, Debard A, Delobel P, Delpierre C, Fourcade C, Marchou B, Martin-Blondel G, Porte M, Mularczyk M, Garipuy D, Saune K, Lepain I, Marcel M, Puntis E, Atoui N, Casanova M, Faucherre V, Jacquet J, Le Moing V, Makinson A, Merle De Boever C, Montoya-Ferrer A, Psomas C, Reynes J, Raffi F, Allavena C, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet C, Jovelin T, Hall N, Bernaud C, Morineau P, Reliquet V, Aubry O, Point P, Besnier M, Larmet L, Hüe H, Pineau S, André-Garnier E, Rodallec A, Choisy P, Vandame S, Huleux T, Ajana F, Alcaraz I, Baclet V, Huleux T, Melliez H, Viget N, Valette M, Aissi E, Allienne C, Meybeck A, Riff B, Bani-Sadr F, Rouger C, Berger J, N'Guyen Y, Lambert D, Kmiec I, Hentzien M, Lebrun D, Migault C, Rey D, Batard M, Bernard-Henry C, Cheneau C, de Mautort E, Fischer P, Partisani M, Priester M, Lucht F, Frésard A, Botelho-Nevers E, Gagneux-Brunon A, Cazorla C, Guglielminotti C, Daoud F, Lutz M, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Corbin V, Aumeran C, Baud O, Casanova S, Coban D, Hustache-Mathieu L, Thiebaut-Drobacheff M, Foltzer A, Gendrin V, Bozon F, Chirouze C, Abel S, Cabié A, Césaire R, Santos GD, Fagour L, Najioullah F, Ouka M, Pierre-François S, Pircher M, Rozé B, Hoen B, Ouissa R, Lamaury I. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"? J Infect 2017; 75:234-241. [PMID: 28579302 DOI: 10.1016/j.jinf.2017.05.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Revised: 03/17/2017] [Accepted: 05/11/2017] [Indexed: 02/07/2023]
Abstract
OBJECTIVES Direct-Acting Antivirals (DAAs) opened a new era in HCV treatment. We report the impact of HCV treatment in French HIV-HCV coinfected patients. METHODS All HIV-HCV patients from the Dat'AIDS cohort followed between 2012 and 2015 were included. HCV status was defined yearly as naive, spontaneous cure, sustained virological response (SVR12), failure or reinfection. RESULTS Among 32,945 HIV-infected patients, 15.2% were positive for anti-HCV antibodies. From 2012 to 2015, HCV incidence rate increased from 0.35%PY to 0.69%PY in MSM, while median incidence was 0.08%PY in other patients. Median reinfection rate was 2.56%PY in MSM and 0.22%PY in other patients. HCV treatment initiation rate rose from 8.2% in 2012 to 29.6% (48.0% in pre-treated patients vs 22.6% in naïve patients). SVR12 rate increased from 68.7% to 95.2%. By the end of 2015, 62.7% of the patients were cured either spontaneously or following SVR. CONCLUSIONS HCV treatment dramatically increased in HIV-HCV patients in France from 2012 to 2015 resulting in HCV cure in nearly two-thirds of the patients in this cohort. Combined with a declining HCV prevalence, the prevalence of active HCV infection among HIV patients will drastically decrease in the forthcoming years.
Collapse
Affiliation(s)
- Pierre Pradat
- Center for Clinical Research, Department of Hepatology, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.
| | - Pascal Pugliese
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet, Nice, France
| | - Isabelle Poizot-Martin
- Immuno-hematology Clinic, Assistance Publique - Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, France; Aix-Marseille University, Inserm U912 (SESSTIM), Marseille, France
| | - Marc-Antoine Valantin
- Department of Infectious Diseases, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France; Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France
| | - Lise Cuzin
- CHU Toulouse, COREVIH, Toulouse, France; Université de Toulouse III, Toulouse, France; INSERM, UMR, 1027, Toulouse, France
| | - Jacques Reynes
- Department of Infectious Diseases, UMI 233 INSERM U1175, CHU de Montpellier, Montpellier, France
| | - Eric Billaud
- Department of Infectious Diseases, Hotel Dieu Hospital, Nantes, France
| | - Thomas Huleux
- Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France
| | - Firouze Bani-Sadr
- Department of Internal Medicine, Infectious Diseases and Clinical Immunology, Hôpital Robert Debré, CHU, Reims, France; Université de Reims Champagne-Ardenne, Faculté de médecine, EA-4684/SFR CAP-SANTE, Reims, France
| | - David Rey
- HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg, France
| | - Anne Frésard
- Department of Infectious Diseases, CHU, Saint-Etienne, France
| | - Christine Jacomet
- Department of Infectious Diseases, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Claudine Duvivier
- Department of Infectious Diseases, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Assistance Publique - Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327, Paris, France
| | - Antoine Cheret
- Department of Internal Medicine, CHU, Bicètre, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327, Paris, France
| | | | - Bruno Hoen
- Faculté de Médecine Hyacinthe Bastaraud, Université des Antilles, and Service de Maladies Infectieuses et Tropicales, Dermatologie et Médecine Interne, and Inserm CIC 1424, Centre Hospitalier Universitaire de Pointe-à-Pitre, Pointe-à-Pitre, France
| | - André Cabié
- Department of Infectious Diseases, CHU de Martinique, Fort-de-France, France; Université des Antilles EA4537 and INSERM CIC1424, Fort-de-France, France
| | - Laurent Cotte
- Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France; INSERM U1052, Lyon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Tetart M, Meybeck A, Assaf A, Valette M, Choisy P, Blondiaux N, Senneville E. Facteurs prédictifs de perte de vue des cas de tuberculose maladie. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
25
|
Loubet P, Lenzi N, Valette M, Foulongne V, Krivine A, Houhou N, Lagathu G, Rogez S, Alain S, Duval X, Galtier F, Postil D, Tattevin P, Vanhems P, Carrat F, Lina B, Launay O. Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. Clin Microbiol Infect 2016; 23:253-259. [PMID: 27903461 PMCID: PMC7128342 DOI: 10.1016/j.cmi.2016.11.014] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Revised: 11/20/2016] [Accepted: 11/22/2016] [Indexed: 11/19/2022]
Abstract
OBJECTIVES The aim of this study was to analyse characteristics and outcome of respiratory syncytial virus (RSV) infection in adults hospitalized with influenza-like illness (ILI). METHODS Patients hospitalized with ILI were included in this prospective, multicentre study carried out in six French hospitals during three consecutive influenza seasons (2012-2015). RSV and other respiratory viruses were detected by multiplex PCR in nasopharyngeal swabs. Risk factors for RSV infection were identified by backward stepwise logistic regression analysis. RESULTS A total of 1452 patients hospitalized with ILI were included, of whom 59% (861/1452) were >65 years and 83% (1211/1452) had underlying chronic illnesses. RSV was detected in 4% (59/1452), and influenza virus in 39% (566/1452). Risk factors for RSV infection were cancer (adjusted OR 2.1, 95% CI 1.1-4.1, p 0.04), and immunosuppressive treatment (adjusted OR 2.0, 95% CI 1.1-3.8, p 0.03). Patients with RSV had a median length of stay of 9 days (6-25), and 57% of them (30/53) had complications, including pneumonia (23/53, 44%) and respiratory failure (15/53, 28%). Fifteen per cent (8/53) were admitted to an intensive care unit, and the in-hospital mortality rate was 8% (4/53). Pneumonia was more likely to occur in patients with RSV than in patients with RSV-negative ILI (44% (23/53) versus 26% (362/1393), p 0.006) or with influenza virus infection (44% versus 28% (157/560), p 0.02). CONCLUSION RSV is an infrequent cause of ILI during periods of influenza virus circulation but can cause severe complications in hospitalized adults. Risk factors for RSV detection in adults hospitalized with ILI include cancer and immunosuppressive treatment. Specific immunization and antiviral therapy might benefit patients at risk.
Collapse
Affiliation(s)
- P Loubet
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, France; Service de Maladies Infectieuses et Tropicales, Hôpital Bichat, AP-HP, Paris, France
| | - N Lenzi
- Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France
| | - M Valette
- CNR Virus Influenza, Institut des Agents Infectieux, GHN, Hospices Civils de Lyon, Lyon, France
| | - V Foulongne
- CHU de Montpellier, Laboratoire de Virologie, Hôpital Saint Eloi, Inserm U 1058, Montpellier, France
| | - A Krivine
- AP-HP, Hôpital Cochin Broca Hôtel-Dieu, Laboratoire de Virologie, Paris, France
| | - N Houhou
- AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Paris, France
| | - G Lagathu
- CHRU Pontchaillou, Laboratoire de Virologie, Rennes, France
| | - S Rogez
- CHU Dupuytren, Service Bactériologie, Virologie, Hygiène, Limoges Cedex, France
| | - S Alain
- CHU Dupuytren, Laboratoire de Virologie, Limoge Cedex, France
| | - X Duval
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, France; Inserm CIC 1425, Hôpital Bichat-Claude Bernard, APHP, Paris, France
| | - F Galtier
- Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France; CHU de Montpellier, Inserm CIC 1411, Hôpital Saint-Eloi, Montpellier, France
| | - D Postil
- CHU Dupuytren, CIC 1435, Limoge Cedex, France
| | - P Tattevin
- CHRU Pontchaillou, Maladies Infectieuses et Réanimation Médicale, CIC INSERM 1414, Rennes, France
| | - P Vanhems
- Service d'Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot, Lyon, France; Emerging Pathogens Laboratory - Fondation Mérieux, Centre International de Recherche en Infectiologie (CIRI) Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France
| | - F Carrat
- Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France; Public health department, Hopital Saint-Antoine, APHP, Paris, France
| | - B Lina
- CNR Virus Influenza, Institut des Agents Infectieux, GHN, Hospices Civils de Lyon, Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Virpath, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Hospices Civils de Lyon, Univ Lyon, Lyon, France
| | - O Launay
- Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France; Inserm, CIC 1417, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Infectious Diseases, CIC Cochin Pasteur, Cochin Broca Hôtel-Dieu hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
| |
Collapse
|
26
|
Fiaux E, Titecat M, Robineau O, Lora-Tamayo J, El Samad Y, Etienne M, Frebourg N, Blondiaux N, Brunschweiler B, Dujardin F, Beltrand E, Loiez C, Cattoir V, Canarelli JP, Hulet C, Valette M, Nguyen S, Caron F, Migaud H, Senneville E. Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations. BMC Infect Dis 2016; 16:568. [PMID: 27737642 PMCID: PMC5064929 DOI: 10.1186/s12879-016-1889-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2015] [Accepted: 10/01/2016] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Outcome of patients with streptococcal prosthetic joint infections (PJIs) is not well known. METHODS We performed a retrospective multicenter cohort study that involved patients with total hip/knee prosthetic joint (THP/TKP) infections due to Streptococcus spp. from 2001 through 2009. RESULTS Ninety-five streptococcal PJI episodes (50 THP and 45 TKP) in 87 patients of mean age 69.1 ± 13.7 years met the inclusion criteria. In all, 55 out of 95 cases (57.9 %) were treated with debridement and retention of the infected implants with antibiotic therapy (DAIR). Rifampicin-combinations, including with levofloxacin, were used in 52 (54.7 %) and 28 (29.5 %) cases, respectively. After a mean follow-up period of 895 days (IQR: 395-1649), the remission rate was 70.5 % (67/95). Patients with PJIs due to S. agalactiae failed in the same proportion as in the other patients (10/37 (27.1 %) versus 19/58 (32.7 %); p = .55). In the univariate analysis, antibiotic monotherapy, DAIR, antibiotic treatments other than rifampicin-combinations, and TKP were all associated with a worse outcome. The only independent variable significantly associated with the patients' outcomes was the location of the prosthesis (i.e., hip versus knee) (OR = 0.19; 95 % CI 0.04-0.93; p value 0.04). CONCLUSIONS The prognosis of streptococcal PJIs may not be as good as previously reported, especially for patients with an infected total knee arthroplasty. Rifampicin combinations, especially with levofloxacin, appear to be suitable antibiotic regimens for these patients.
Collapse
Affiliation(s)
- E Fiaux
- Infectious Diseases Department, University Hospital of Rouen, Rouen, France
| | - M Titecat
- Laboratory of Microbiology, University Hospital of Lille, Lille, France
| | - O Robineau
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, 135 rue du Président Coty, 59200, Tourcoing, France
| | - J Lora-Tamayo
- Unit of Infectious Diseases Hospital 12 de Octubre of Madrid, Madrid, Spain
| | - Y El Samad
- Infectious Diseases Department, University Hospital of Amiens, Amiens, France
| | - M Etienne
- Infectious Diseases Department, University Hospital of Rouen, Rouen, France
| | - N Frebourg
- Laboratory of Microbiology, University Hospital of Rouen, Rouen, France
| | - N Blondiaux
- Laboratory of Microbiology, Gustave Dron Hospital of Tourcoing, Tourcoing, France
| | - B Brunschweiler
- Orthopaedic Surgery Unit, University Hospital of Amiens, Amiens, France
| | - F Dujardin
- Orthopaedic Surgery Unit, University Hospital of Rouen, Rouen, France
| | - E Beltrand
- Orthopaedic Surgery Unit, Gustave Dron Hospital of Tourcoing, Tourcoing, France
| | - C Loiez
- Laboratory of Microbiology, University Hospital of Lille, Lille, France
| | - V Cattoir
- Laboratory of Microbiology, University Hospital of Caen, Caen, France
| | - J P Canarelli
- Orthopaedic Surgery Unit, University Hospital of Amiens, Amiens, France
| | - C Hulet
- Orthopaedic Surgery Unit, University Hospital of Caen, Caen, France
| | - M Valette
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, 135 rue du Président Coty, 59200, Tourcoing, France
| | - S Nguyen
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, 135 rue du Président Coty, 59200, Tourcoing, France
| | - F Caron
- Infectious Diseases Department, University Hospital of Rouen, Rouen, France
| | - H Migaud
- Orthopaedic Surgery Unit, University Hospital of Lille, Lille, France
| | - E Senneville
- Infectious Diseases Department, Gustave Dron Hospital of Tourcoing, 135 rue du Président Coty, 59200, Tourcoing, France. .,French Reference Center for Osteo-Articular Infections (CRIOAC Lille-Tourcoing), Faculty Hospital of Lille, Lille, France.
| | | |
Collapse
|
27
|
Bal A, Pichon M, Picard C, Billaud G, Casalegno J, Bouscambert-Duchamp M, Escuret V, Schuffenecker I, Valette M, Lina B, Morfin F, Josset L. Metagenomic analysis of the respiratory virome associated with acute respiratory illness of unknown etiology in infants. J Clin Virol 2016. [DOI: 10.1016/j.jcv.2016.08.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Grossi O, Asseray N, Bourigault C, Corvec S, Valette M, Navas D, Happi-Djeukou L, Touchais S, Bémer P, Boutoille D. Gram-negative prosthetic joint infections managed according to a multidisciplinary standardized approach: risk factors for failure and outcome with and without fluoroquinolones. J Antimicrob Chemother 2016; 71:2593-7. [PMID: 27278900 DOI: 10.1093/jac/dkw202] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Accepted: 05/04/2016] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES To describe the outcome and risk factors for treatment failure of 76 Gram-negative bacilli (GNB) prosthetic joint infections (PJIs) managed with a curative intent according to a standardized protocol derived from published guidelines. METHODS We analysed data from all the cases of GNB-PJI treated surgically over an 8 year period. Treatment failure was defined as persistence or recurrence of PJI signs during follow-up, resulting in additional surgery and/or antibiotic administration or death. RESULTS Treatment failure within the follow-up period (median = 2.6 years) was observed in 16 of 76 (21.1%) patients. The failure rate was similar whether the patients were treated with fluoroquinolones in the whole cohort (22.4% versus 16.7%, P = 0.75) and after stratification according to the surgical procedure. The low failure rate observed in patients not receiving fluoroquinolones might be explained by the standardized attitude of maintaining intravenous β-lactams throughout treatment duration (median = 90 days). In multivariate analysis, C-reactive protein level ≥175 mg/L was significantly associated with treatment failure (adjusted HR = 7.75, 95% CI = 2.66-22.59, P < 0.0001). CONCLUSIONS Management according to standardized procedures may improve the prognosis of GNB-PJI. Intravenous β-lactams, continued for 3 months, should be considered an effective alternative to fluoroquinolones.
Collapse
Affiliation(s)
- O Grossi
- Service des Maladies Infectieuses, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France Département de Médecine Interne - Infectiologie, Nouvelles Cliniques Nantaises, 3 rue Eric Tabarly, 44277 Nantes cedex 2, France
| | - N Asseray
- Service des Maladies Infectieuses, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | - C Bourigault
- Unité de Gestion du Risque Infectieux, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | - S Corvec
- Service de Bactériologie, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | - M Valette
- Service des Maladies Infectieuses, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | - D Navas
- Service de Pharmacie Clinique, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | - L Happi-Djeukou
- Clinique Chirurgicale Orthopédique et Traumatologique, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | - S Touchais
- Clinique Chirurgicale Orthopédique et Traumatologique, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | - P Bémer
- Service de Bactériologie, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | - D Boutoille
- Service des Maladies Infectieuses, Centre Hospitalier Universitaire, 1 place Alexis Ricordeau, 44093 Nantes cedex 1, France
| | | |
Collapse
|
29
|
Deconinck L, Robineau O, Valette M, Choisy P, Bocket L, Meybeck A, Ajana F. VIH-21 - Place du tropisme CCR5 pour l’initiation et le maintien du maraviroc chez les patients infectés par le VIH : suivi dans la vraie vie. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30566-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Robineau O, Deconinck L, Hulleux T, Baclet V, Valette M, Choisy P, Senneville E, Ajana F. HEP-05 - Prise en charge de l’hépatite C aiguë chez les patients infectés par le VIH : leçons d’une cohorte historique. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30382-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
Baclet V, Valette M, Meybeck A, Ajana F, Huleux T, Viget N, Alcaraz I, Melliez H, Senneville E. IST-12 - Estimation de la prévalence multisites de Chlamydia trachomatis et Neisseria gonorrheae et des facteurs associés chez les patients récemment découverts infectés par le VIH. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30443-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Pasquet A, Robineau O, D’Elia P, Valette M, Vandamme S, Patoz P, Leroy O, Voitot J, Senneville E. IAS-01 - Caractéristiques et pronostic des patients atteints d’une infection de prothèse vasculaire (IPV) suivie par émission de positons (TEP) : une cohorte prospective de 67 patients. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30398-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Okumura Y, Gobin R, Knaster J, Heidinger R, Ayala JM, Bolzon B, Cara P, Chauvin N, Chel S, Gex D, Harrault F, Ichimiya R, Ihara A, Ikeda Y, Kasugai A, Kikuchi T, Kitano T, Komata M, Kondo K, Maebara S, Marqueta A, O'Hira S, Perez M, Phillips G, Pruneri G, Sakamoto K, Scantamburlo F, Senée F, Shinto K, Sugimoto M, Takahashi H, Usami H, Valette M. Operation and commissioning of IFMIF (International Fusion Materials Irradiation Facility) LIPAc injector. Rev Sci Instrum 2016; 87:02A739. [PMID: 26931957 DOI: 10.1063/1.4936248] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The objective of linear IFMIF prototype accelerator is to demonstrate 125 mA/CW deuterium ion beam acceleration up to 9 MeV. The injector has been developed in CEA Saclay and already demonstrated 140 mA/100 keV deuterium beam [R. Gobin et al., Rev. Sci. Instrum. 85, 02A918 (2014)]. The injector was disassembled and delivered to the International Fusion Energy Research Center in Rokkasho, Japan. After reassembling the injector, commissioning has started in 2014. Up to now, 100 keV/120 mA/CW hydrogen and 100 keV/90 mA/CW deuterium ion beams have been produced stably from a 10 mm diameter extraction aperture with a low beam emittance of 0.21 π mm mrad (rms, normalized). Neutron production by D-D reaction up to 2.4 × 10(9) n/s has been observed in the deuterium operation.
Collapse
Affiliation(s)
- Y Okumura
- IFMIF/EVEDA Project Team, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - R Gobin
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - J Knaster
- IFMIF/EVEDA Project Team, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - R Heidinger
- F4E, Fusion for Energy, BFD Department, D-85748 Garching, Germany
| | - J-M Ayala
- IFMIF/EVEDA Project Team, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - B Bolzon
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - P Cara
- F4E, Fusion for Energy, BFD Department, D-85748 Garching, Germany
| | - N Chauvin
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - S Chel
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - D Gex
- F4E, Fusion for Energy, BFD Department, D-85748 Garching, Germany
| | - F Harrault
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - R Ichimiya
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - A Ihara
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - Y Ikeda
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - A Kasugai
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - T Kikuchi
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - T Kitano
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - M Komata
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - K Kondo
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - S Maebara
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - A Marqueta
- IFMIF/EVEDA Project Team, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - S O'Hira
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - M Perez
- IFMIF/EVEDA Project Team, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - G Phillips
- F4E, Fusion for Energy, BFD Department, D-85748 Garching, Germany
| | - G Pruneri
- IFMIF/EVEDA Project Team, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - K Sakamoto
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - F Scantamburlo
- IFMIF/EVEDA Project Team, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - F Senée
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - K Shinto
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - M Sugimoto
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - H Takahashi
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - H Usami
- JAEA, Division of Rokkasho BA Project, Obuchi-Omotedate, 039-3212 Rokkasho, Aomori, Japan
| | - M Valette
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| |
Collapse
|
34
|
Shinto K, Senée F, Ayala JM, Bolzon B, Chauvin N, Gobin R, Ichimiya R, Ihara A, Ikeda Y, Kasugai A, Kitano T, Kondo K, Marqueta A, Okumura Y, Takahashi H, Valette M. Measurement of ion species in high current ECR H⁺/D⁺ ion source for IFMIF (International Fusion Materials Irradiation Facility). Rev Sci Instrum 2016; 87:02A727. [PMID: 26931945 DOI: 10.1063/1.4933342] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Ion species ratio of high current positive hydrogen/deuterium ion beams extracted from an electron-cyclotron-resonance ion source for International Fusion Materials Irradiation Facility accelerator was measured by the Doppler shift Balmer-α line spectroscopy. The proton (H(+)) ratio at the middle of the low energy beam transport reached 80% at the hydrogen ion beam extraction of 100 keV/160 mA and the deuteron (D(+)) ratio reached 75% at the deuterium ion beam extraction of 100 keV/113 mA. It is found that the H(+) ratio measured by the spectroscopy gives lower than that derived from the phase-space diagram measured by an Allison scanner type emittance monitor. The H(+)/D(+) ratio estimated by the emittance monitor was more than 90% at those extraction currents.
Collapse
Affiliation(s)
- K Shinto
- Rokkasho Fusion Institute, Japan Atomic Energy Agency, Rokkasho, Aomori 039-3212, Japan
| | - F Senée
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - J-M Ayala
- IFMIF/EVEDA Project Team, Rokkasho, Aomori 039-3212, Japan
| | - B Bolzon
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - N Chauvin
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - R Gobin
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| | - R Ichimiya
- Rokkasho Fusion Institute, Japan Atomic Energy Agency, Rokkasho, Aomori 039-3212, Japan
| | - A Ihara
- Rokkasho Fusion Institute, Japan Atomic Energy Agency, Rokkasho, Aomori 039-3212, Japan
| | - Y Ikeda
- Rokkasho Fusion Institute, Japan Atomic Energy Agency, Rokkasho, Aomori 039-3212, Japan
| | - A Kasugai
- Rokkasho Fusion Institute, Japan Atomic Energy Agency, Rokkasho, Aomori 039-3212, Japan
| | - T Kitano
- Rokkasho Fusion Institute, Japan Atomic Energy Agency, Rokkasho, Aomori 039-3212, Japan
| | - K Kondo
- Rokkasho Fusion Institute, Japan Atomic Energy Agency, Rokkasho, Aomori 039-3212, Japan
| | - A Marqueta
- IFMIF/EVEDA Project Team, Rokkasho, Aomori 039-3212, Japan
| | - Y Okumura
- IFMIF/EVEDA Project Team, Rokkasho, Aomori 039-3212, Japan
| | - H Takahashi
- Rokkasho Fusion Institute, Japan Atomic Energy Agency, Rokkasho, Aomori 039-3212, Japan
| | - M Valette
- Commissariat à l'Energie Atomique et aux Energies Alternatives, CEA/Saclay, DSM/IRFU, 91191 Gif/Yvette, France
| |
Collapse
|
35
|
Alcaraz I, Robineau O, Blondiaux N, Baclet V, Valette M, Huleux T, Ajana F, Senneville E. Dépistage systématique urinaire, ano-rectal et pharyngé du portage de Chlamydia trachomatis (CT) et Neisseria gonorrhoeae (NG) chez 369 patients HSH vivant avec le VIH (PVVIH). Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Senneville E, Tone A, Valette M, Nguyen S. Response to Comment on Tone et al. Six-Week Versus Twelve-Week Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study. Diabetes Care 2015;38:302-307. Diabetes Care 2015; 38:e145. [PMID: 26294781 DOI: 10.2337/dc15-1076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- Eric Senneville
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| | - Alina Tone
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| | - Michel Valette
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| | - Sophie Nguyen
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| |
Collapse
|
37
|
Bouscambert M, Valette M, Lina B. Rapid bedside tests for diagnosis, management, and prevention of nosocomial influenza. J Hosp Infect 2015; 89:314-8. [DOI: 10.1016/j.jhin.2014.12.017] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Accepted: 12/23/2014] [Indexed: 11/29/2022]
|
38
|
Tone A, Nguyen S, Devemy F, Topolinski H, Valette M, Cazaubiel M, Fayard A, Beltrand É, Lemaire C, Senneville É. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 2015;38:302-307. Diabetes Care 2015; 38:735. [PMID: 25805867 DOI: 10.2337/dc15-er04b] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
39
|
Tone A, Nguyen S, Devemy F, Topolinski H, Valette M, Cazaubiel M, Fayard A, Beltrand É, Lemaire C, Senneville É. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 2015; 38:302-7. [PMID: 25414157 DOI: 10.2337/dc14-1514] [Citation(s) in RCA: 116] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Little is known about the optimal duration of antibiotic therapy for diabetic foot osteomyelitis (DFO). This study sought to compare the effectiveness of 6 versus 12 weeks of antibiotic therapy in patients with DFO treated nonsurgically (i.e., antibiotics alone). RESEARCH DESIGN AND METHODS This was a prospective randomized trial comparing 6- versus 12-week duration of antibiotic treatment. Remission of osteomyelitis during the monitoring period was defined as complete and persistent (>4 weeks) healing of the wound (if present initially), absence of recurrent infection at the initial site or that of adjacent rays, and no need for surgical bone resection or amputation at the end of a follow-up period of at least 12 months after completion of antibiotic treatment. RESULTS Forty patients followed at five French general hospitals were randomized between January 2007 and January 2009, with 20 treated for 6 weeks and 20 treated for 12 weeks with antibiotics. The two groups were comparable for all variables recorded at inclusion in the study. Remission was obtained in 26 (65%) patients, with no significant differences between patients treated for 6 versus 12 weeks (12/20 vs. 14/20, respectively; P = 0.50). We did not identify any significant parameters associated with patient outcome. Fewer patients treated for 6 weeks experienced gastrointestinal adverse events related to antimicrobial therapy compared with patients treated for 12 weeks (respectively, 15 vs. 45%; P = 0.04). CONCLUSIONS The present multicenter prospective randomized study provides data suggesting that 6-week duration of antibiotic therapy may be sufficient in patients with DFO for whom nonsurgical treatment is considered.
Collapse
Affiliation(s)
- Alina Tone
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| | - Sophie Nguyen
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| | - Fabrice Devemy
- Diabetology Unit, General Hospital of Lens, Lens, France
| | | | - Michel Valette
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| | | | - Armelle Fayard
- Diabetology Unit, General Hospital of Arras, Arras, France
| | - Éric Beltrand
- Orthopedic Surgery Unit, Gustave Dron Hospital, Tourcoing, France
| | | | - Éric Senneville
- Infectious Diseases Department, Gustave Dron Hospital, Tourcoing, France
| |
Collapse
|
40
|
Mosnier A, Daviaud I, Vabret A, Valette M, Enouf V, Debost E, Cohen JM. I-02: Virus respiratoire syncytial : un impact non négligeable chez les seniors. Med Mal Infect 2014. [DOI: 10.1016/s0399-077x(14)70191-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Pasquet A, Valette M, Legout L, D’Elia PV, Sarraz-Bournet B, Leroy O, Senneville E. O-05: Caractéristiques et pronostic des patients hospitalisés pour une infection de prothèse vasculaire (IPV) à staphylocoque. Med Mal Infect 2014. [DOI: 10.1016/s0399-077x(14)70284-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
42
|
Nguyen S, Valette M, Tone A, Choisy P, Descamps D, Senneville E. G-02: Évaluation prospective de l’incidence des infections de prothèses articulaires d’origine hématogène (IPA-H) au décours d’une bactériémie. Med Mal Infect 2014. [DOI: 10.1016/s0399-077x(14)70171-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
Biekre R, Lasfar NB, Viget N, Valette M, Baclet V, Huleux T, Senneville E, Ajana F. Long-term protection of hepatitis B vaccine in HIV-infected patients. BMC Infect Dis 2014. [PMCID: PMC4220872 DOI: 10.1186/1471-2334-14-s2-o7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Le Blanc C, Valette M, Debout A, Sagan C, Defrance C, Boutoille D, Corne F, Nicolet L, Magnan A. Complication inattendue d’un réveillon à l’hôpital. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Legout L, Delia P, Sarraz-Bournet B, Rouyer C, Massongo M, Valette M, Leroy O, Haulon S, Senneville E. Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin. BMC Infect Dis 2014; 14:228. [PMID: 24775563 PMCID: PMC4049509 DOI: 10.1186/1471-2334-14-228] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Accepted: 03/12/2014] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND There exists considerable debate concerning management of prosthetic vascular graft infection (PVGI), especially in terms of antimicrobial treatment. This report studies factors associated with treatment failure in a cohort of patients with staphylococcal PVGI, along with the impact of rifampin (RIF). METHODS All data on patients with PVGI between 2006 and 2010 were reviewed. Cure was defined as the absence of evidence of infection during the entire post-treatment follow-up for a minimum of one year. Failure was defined as any other outcome. RESULTS 84 patients (72 M/12 F, median age 64.5 ± 11 y) with diabetes mellitus (n = 25), obesity (n = 48), coronary artery disease (n = 48), renal failure (n = 24) or COPD (n = 22) were treated for PVGI (median follow-up was 470 ± 469 d). PVGI was primarily intracavitary (n = 47). Staphylococcus aureus (n = 65; including 17 methicillin-resistant S. aureus) and coagulase-negative Staphylocococcus (n = 22) were identified. Surgical treatment was performed in 71 patients. In univariate analysis, significant risk factors associated with failure were renal failure (p = 0.04), aortic aneurysm (p = 0.03), fever (p = 0.009), aneurysm disruption (p = 0.02), septic shock in the peri-operative period (p = 0.005) and antibiotic treatment containing RIF (p = 0.03). In multivariate analysis, 2 variables were independently associated with failure:septic shock [OR 4.98: CI 95% 1.45-16.99; p=0.01] and antibiotic containing rifampin [OR: 0.32: CI95% 0.10-0.96; p=0.04]. CONCLUSION Results of the present study suggest that fever, septic shock and non-use of antibiotic treatment containing RIF are associated with poor outcome.
Collapse
Affiliation(s)
- Laurence Legout
- Infectious Diseases Department, Dron Hospital of Tourcoing, Rue du Président Coty, Tourcoing 59208, France
| | - Piervito Delia
- Department of Vascular Surgery, Dron Hospital of Tourcoing, Tourcoing, France
- Department of Vascular Surgery, University Hospital of Lille, Lille, France
| | | | - Cécile Rouyer
- Infectious Diseases Department, Dron Hospital of Tourcoing, Rue du Président Coty, Tourcoing 59208, France
| | - Massongo Massongo
- Infectious Diseases Department, Dron Hospital of Tourcoing, Rue du Président Coty, Tourcoing 59208, France
| | - Michel Valette
- Infectious Diseases Department, Dron Hospital of Tourcoing, Rue du Président Coty, Tourcoing 59208, France
| | - Olivier Leroy
- Intensive Care and Infectious Diseases Unit, Dron Hospital of Tourcoing, Tourcoing, France
| | - Stephan Haulon
- Department of Vascular Surgery, University Hospital of Lille, Lille, France
| | - Eric Senneville
- Infectious Diseases Department, Dron Hospital of Tourcoing, Rue du Président Coty, Tourcoing 59208, France
| |
Collapse
|
46
|
Chéné AL, Cellerin L, Valette M, Sagan C, Liberge R, Magnan A. Traitement endobronchique d’une tumeur carcinoïde. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2013.04.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
47
|
Valette M, Bellisle F, Carette C, Poitou C, Dubern B, Paradis G, Hercberg S, Muzard L, Clément K, Czernichow S. Eating behaviour in obese patients with melanocortin-4 receptor mutations: a literature review. Int J Obes (Lond) 2012; 37:1027-35. [PMID: 23147118 DOI: 10.1038/ijo.2012.169] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2012] [Revised: 09/07/2012] [Accepted: 09/09/2012] [Indexed: 11/09/2022]
Abstract
Melanocortin-4 receptor (MC4R) mutations are the most common known cause of monogenic obesity and an important contributor to polygenic obesity. MC4R mutations with partial or total loss of function, as well as the variant rs17782313 mapped near MC4R, are positively associated with obesity. MC4R is involved in the leptin-melanocortin signalling system, located in hypothalamic nuclei, that controls food intake via both anorexigenic or orexigenic signals. Impairment in this receptor might affect eating behaviours. Thus, in the case of MC4R mutation carriers, obesity could be related, at least partly, to inadequate control over eating behaviours. Many published studies address eating behaviours in MC4R mutation carriers. Most studies focus on binge eating disorder, whereas others examine various aspects of intake and motivation. Up to now, no evaluation of this literature has been performed. In this review, we examine the available literature on eating behaviours in carriers of MC4R mutations and variant rs17782313 near MC4R gene. We address binge eating disorder, bulimia nervosa, mealtime hyperphagia, snacking, psychological factors, satiety responsiveness and intake of energy and macro/micronutrient. In a small number of studies, MC4R mutations seem to impair eating behaviours or motivation, but no clear causal effects can be found in the balance of the evidence presented. Improvements in methodologies will be necessary to clarify the behavioural effects of MC4R mutations.
Collapse
Affiliation(s)
- M Valette
- Nutritional Epidemiology Research Unit-UMR U557 INSERM, Paris 13 University, CRNH-IdF, Bobigny, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Valette M, Aubin G, Bressollette-Bodin C, Corne F, Coste-Burel M, Magnan A. Détection des génomes de Cytomégalovirus et d’Herpès Simplex Virus dans les lavages broncho-alvéolaires au décours des pneumopathies : fréquence et interprétation. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2012.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Meybeck A, Lecomte L, Valette M, Van Grunderbeeck N, Boussekey N, Chiche A, Georges H, Yazdanpanah Y, Leroy O. Should highly active antiretroviral therapy be prescribed in critically ill HIV-infected patients during the ICU stay? A retrospective cohort study. AIDS Res Ther 2012; 9:27. [PMID: 23020962 PMCID: PMC3544704 DOI: 10.1186/1742-6405-9-27] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2011] [Accepted: 09/21/2012] [Indexed: 01/04/2023] Open
Abstract
Background The impact of highly active antiretroviral therapy (HAART) in HIV-infected patients admitted to the intensive care unit (ICU) remains controversial. We evaluate impact of HAART prescription in HIV-infected patients admitted to the ICU of Tourcoing Hospital from January 2000 to December 2009. Results There were 91 admissions concerning 85 HIV-infected patients. Reasons for ICU admission were an AIDS-related diagnosis in 46 cases (51%). Fifty two patients (57%) were on HAART at the time of ICU admission, leading to 21 immunovirologic successes (23%). During the ICU stay, HAART was continued in 29 patients (32%), and started in 3 patients (3%). Only one patient experienced an adverse event related to HAART. Mortality rate in ICU and 6 months after ICU admission were respectively 19% and 27%. Kaplan-Meier estimates of the cumulative unajusted survival probability over 6 months were higher in patients treated with HAART during the ICU stay (Log rank: p = 0.04). No benefit of HAART in ICU was seen in the adjusted survival proportion at 6 months or during ICU stay. Prescription of HAART during ICU was associated with a trend to lower incidence of new AIDS-related events at 6 months (respectively 17% and 34% with and without HAART, p = 0.07), and with higher incidence of antiretroviral resistance after ICU stay (respectively 25% and 7% with and without HAART, p = 0.02). Conclusions Our results suggest a lower death rate over 6 months in critically ill HIV-infected patients taking HAART during ICU stay. The optimal time to prescribe HAART in critically ill patients needs to be better defined.
Collapse
|
50
|
Senneville E, Joulie D, Legout L, Valette M, Dezèque H, Beltrand E, Roselé B, d'Escrivan T, Loïez C, Caillaux M, Yazdanpanah Y, Maynou C, Migaud H. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2012; 53:334-40. [PMID: 21810745 PMCID: PMC3148259 DOI: 10.1093/cid/cir402] [Citation(s) in RCA: 173] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Variables associated with the outcome of patients treated for prosthetic joint infections (PJIs) due to Staphylococcus aureus are not well known. METHODS The medical records of patients treated surgically for total hip or knee prosthesis infection due to S. aureus were reviewed. Remission was defined by the absence of local or systemic signs of implant-related infection assessed during the most recent contact with the patient. RESULTS After a mean posttreatment follow-up period of 43.6 ± 32.1 months, 77 (78.6%) of 98 patients were in remission. Retention of the infected implants was not associated with a worse outcome than was their removal. Methicillin-resistant S. aureus (MRSA)-related PJIs were not associated with worse outcome, compared with methicillin-susceptible S. aureus (MSSA)-related PJIs. Pathogens identified during revision for failure exhibited no acquired resistance to antibiotics used as definitive therapy, in particular rifampin. In univariate analysis, parameters that differed between patients whose treatment did or did not fail were: American Society of Anesthesiologists (ASA) score, prescription of adequate empirical postsurgical antibiotic therapy, and use of rifampin combination therapy upon discharge from hospital. In multivariate analysis, ASA score ≤2 (odds ratio [OR], 6.87 [95% confidence interval {CI}, 1.45-32.45]; P = .04) and rifampin-fluoroquinolone combination therapy (OR, 0.40 [95% CI, 0.17-0.97]; P = .01) were 2 independent variables associated with remission. CONCLUSIONS The results of the present study suggest that the ASA score significantly affects the outcome of patients treated for total hip and knee prosthetic infections due to MSSA or MRSA and that rifampin combination therapy is associated with a better outcome for these patients when compared with other antibiotic regimens.
Collapse
Affiliation(s)
- Eric Senneville
- Centre National de Référence des Infections Ostéo-Articulaires Nord-Ouest, Roger Salengro Faculty Hospital of Lille, Lille, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|